About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
1233 genotypes with 1773 annotations displayed of selected term and subterms
Searched Term: increased gland tumor incidence
Allelic Composition
(Genetic Background)
Annotated Term Reference
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi)
increased prostate gland adenocarcinoma incidence J:207558
increased prostate intraepithelial neoplasia incidence J:207558
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
increased mammary adenocarcinoma incidence J:87544
Actbtm1(PyVT)Arge/Actb+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv)
increased mammary adenocarcinoma incidence J:87544
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
increased mammary gland tumor incidence J:147458
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
increased mammary gland tumor incidence J:147458
Ahrtm1Bra/Ahr+
Tg(TRAMP)8247Ng/0

(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
increased prostate gland tumor incidence J:118152
Ahrtm1Bra/Ahrtm1Bra
Tg(TRAMP)8247Ng/0

(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
increased prostate gland tumor incidence J:118152
Aicdatm1(cre)Mnz/Aicda+
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153656
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6)
increased pituitary adenoma incidence J:165349
increased prolactinoma incidence J:165349
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi
Fancd2tm1Hou/Fancd2tm1Hou

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
increased T cell derived lymphoma incidence J:193232
Amhtm1Bhr/Amh+
Amhr2tm1Bhr/Amhr2tm1Bhr

(involves: 129S7/SvEvBrd * C57BL/6)
increased testis tumor incidence J:36027
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inha+

(involves: 129S7/SvEvBrd * C57BL/6)
increased testis tumor incidence J:36027
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inhatm1Bay

(involves: 129S7/SvEvBrd)
increased granulosa cell tumor incidence J:36027
increased Leydig cell tumor incidence J:36027
increased testis tumor incidence J:36027
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+

(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ)
increased granulosa cell tumor incidence J:149060
increased ovary tumor incidence J:142150
increased testis tumor incidence J:149060
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
Amhr2tm3(cre)Bhr/Amhr2+
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N)
increased granulosa cell tumor incidence J:236161
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk

(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
Smad9tm1Jfm/Smad9tm1Jfm

(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
ApcM1Tno/Apc+
(involves: C57BL/6 * DBA/2JJcl)
increased mammary gland tumor incidence J:218227
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
increased mammary adenocarcinoma incidence J:218227
increased mammary gland tumor incidence J:218227
ApcMin/Apc+
(involves: C57BL/6J)
increased mammary adenocarcinoma incidence J:94108
ApcMin/Apc+
(B6.Cg-Brca2tm1Mbn ApcMin)
increased mammary gland tumor incidence J:67445
ApcMin/Apc+
(B6(AKR)-ApcMin)
increased mammary gland tumor incidence J:15101
ApcMin/Apc+
Brca2tm1Mbn/Brca2+

(B6.Cg-Brca2tm1Mbn ApcMin)
increased mammary gland tumor incidence J:67445
ApcMin/Apc+
Tcf7tm1Cle/Tcf7tm1Cle

(involves: 129P2/OlaHsd * C57BL/6J)
increased mammary adenoacanthoma incidence J:57721
increased salivary gland tumor incidence J:57721
ApcMin/Apc+
Trp53tm1Mlh/Trp53tm1Mlh

(involves: 129P2/OlaHsd * C57BL/6 * SWR)
increased pancreatic acinar cell carcinoma incidence J:29664
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased mammary adenocarcinoma incidence J:94108
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased mammary adenocarcinoma incidence J:61978
increased mammary gland tumor incidence J:61978
Apctm1Mmt/Apc+
Smad4tm1Mmt/Smad4+

(involves: 129S2/SvPas * C57BL/6)
increased pancreatic ductal adenocarcinoma incidence J:46242
Apctm1Rsmi/Apctm1Rsmi
Pgrtm2(cre)Lyd/Pgr+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased granulosa cell tumor incidence J:210095
increased ovary tumor incidence J:210095
Apctm1Tno/Apc+
Brf1tm1Arte/Brf1tm1Arte
Tg(Cyp1a1-cre)1Dwi/0

(involves: C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:285667
Apctm1Tno/Apc+
Tg(CDX2-cre)101Erf/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:126018
Apctm1Tno/Apctm1Tno
Ptentm2Mak/Ptentm2Mak

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased ovarian carcinoma incidence J:120955
Apctm1Tno/Apctm1Tno
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
increased prostate gland adenocarcinoma incidence J:120308
increased prostate intraepithelial neoplasia incidence J:120308
Apctm2Rak/Apc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
increased pancreas tumor incidence J:234310
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
increased mammary adenocarcinoma incidence J:151494
increased mammary gland tumor incidence J:151494
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
increased mammary adenocarcinoma incidence J:204440, J:151494
increased mammary gland tumor incidence J:151494
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
increased mammary adenocarcinoma incidence J:151494
Apctm2Rfo/Apc+
Smad4E6sad/Smad4+

(involves: 129P2/OlaHsd * C57BL/6J)
increased mammary adenocarcinoma incidence J:151494
Apmt1FVB/NJ/Apmt1FVB/NJ
(involves: FVB/NJ * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt1FVB/NJ/Apmt1FVB/NJ
Apmt2I/LnJ/Apmt2FVB/NJ

(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt1FVB/NJ/Apmt1I/LnJ
(involves: FVB/NJ * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt2I/LnJ/?
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
increased mammary gland tumor incidence J:64663
ArTfm/Y
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
increased testis tumor incidence J:140803
ArTfm/Y
Tg(TSPY)9Jshm/0

(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
increased testis tumor incidence J:140803
Artm1(AR)Dmr/Y
Tg(TRAMP)8247Ng/0

(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:108849
Artm1Verh/Y
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:172730
Artm2(AR)Dmr/Y
Tg(TRAMP)8247Ng/0

(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:108849
Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Tg(TRAMP)8247Ng/0

(involves: C57BL/6 * C57BL/6J * CBA)
increased prostate gland tumor incidence J:170092
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * CD-1)
increased ovarian carcinoma incidence J:219794
increased ovary tumor incidence J:219794
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
increased gland tumor incidence J:176672
increased granulosa cell tumor incidence J:176672
increased Harderian gland adenocarcinoma incidence J:176672
increased T cell derived lymphoma incidence J:176672
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
increased T cell derived lymphoma incidence J:34193
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
increased T cell derived lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:90941
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atmtm1Awb
Rad52tm1Aps/Rad52tm1Aps

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:90941
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:35914
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:61201
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
increased T cell derived lymphoma incidence J:69726
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
increased ovary tumor incidence J:78527
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
increased T cell derived lymphoma incidence J:69726
Atmtm2.1Fwa/Atmtm2.1Fwa
Tg(VAV1-cre)1Graf/0

(involves: 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:277750
B2mtm1Unc/B2mtm1Unc
Prkdcscid/Prkdcscid

(NOD.Cg-B2mtm1Unc Prkdcscid)
increased T cell derived lymphoma incidence J:102141
Bap1em1Test/Bap1+
(involves: FVB)
increased granulosa cell tumor incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased ovary tumor incidence J:231692
Bap1em2Test/Bap1+
(involves: FVB)
increased granulosa cell tumor incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased ovary tumor incidence J:231692
increased pancreatic islet cell carcinoma incidence J:231692
Bap1em3Test/Bap1+
(involves: FVB)
increased granulosa cell tumor incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased ovary tumor incidence J:231692
Bard1tm1Thl/Bard1tm2Thl
Waptm1(cre)Arge/0

(involves: 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129/Sv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Waptm1(cre)Arge/0

(involves: 129/Sv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(Ins2-cre)25Mgn/0
Tg(RIP1-Tag)2Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA)
increased pancreas tumor incidence J:146436
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(RIP1-Tag)2Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA)
increased pancreas tumor incidence J:146436
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:186117
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
increased mammary gland tumor incidence J:86953
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
increased pancreas adenoma incidence J:105076
increased pancreatic acinar cell carcinoma incidence J:105076
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
increased mammary adenocarcinoma incidence J:117330
Bin1tm1Gcp/Bin1tm2Gcp
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
increased granulosa cell tumor incidence J:117330
increased mammary gland tumor incidence J:117330
Bin1tm2Gcp/Bin1+
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
increased mammary gland tumor incidence J:117330
Blmtm1Ches/Blmtm4Ches
Tg(Hsp70-1-cre)6Arge/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
increased mammary gland tumor incidence J:112115
Blmtm1Ches/Blmtm4Ches
Tg(KLK3-cre)1Ches/0

(involves: 129S6/SvEvTac)
increased mammary gland tumor incidence J:112115
Blmtm1Ches/Blmtm4Ches
Tg(LGB-cre)74Acl/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:112115
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
increased T cell derived lymphoma incidence J:133084
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Ctnnb1tm1Mmt/Ctnnb1+
Krt14tm1.1(cre)Wbm/Krt14+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
increased salivary gland tumor incidence J:199091
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
increased gland tumor incidence J:170095
increased pheochromocytoma incidence J:170095
Braftm1Cpri/Braftm1Cpri
Gnastm3Lsw/Gnastm3Lsw
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr)
increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * FVB/NCr)
increased thyroid carcinoma incidence J:168249
increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tshrtm1Rmar/Tshrtm1Rmar
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr)
increased thyroid tumor incidence J:168249
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Tg(Tg-cre/ERT2)#Mmcm/0

(involves: 129P2/OlaHsd)
increased thyroid carcinoma incidence J:172205
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased prostate gland adenocarcinoma incidence J:191327
increased prostate gland tumor incidence J:191327
increased prostate intraepithelial neoplasia incidence J:191327
Brca1tm1Aash/Brca1tm1Aash
Tg(LGB-cre)74Acl/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased mammary gland tumor incidence J:119996
increased salivary adenocarcinoma incidence J:119996
Brca1tm1Aash/Brca1tm1Aash
Trp53tm1Brd/Trp53+
Tg(LGB-cre)74Acl/0

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
increased mammary gland ductal carcinoma incidence J:119996
increased mammary gland tumor incidence J:119996
increased salivary adenocarcinoma incidence J:119996
Brca1tm1Arge/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Brca1tm1Bhk/Brca1+
(C.129P2-Brca1tm1Bhk)
increased mammary gland tumor incidence J:198018
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi

(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
increased mammary adenocarcinoma incidence J:198018
increased mammary gland tumor incidence J:198018
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
increased ovarian carcinoma incidence J:189304
increased ovary tumor incidence J:189304
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
increased mammary gland tumor incidence J:178595
Brca1tm1Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * Black Swiss * FVB)
increased mammary adenocarcinoma incidence J:54533
increased mammary gland tumor incidence J:54533
Brca1tm1Cxd/Brca1tm2Cxd
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * Black Swiss)
increased mammary gland tumor incidence J:54533
Brca1tm1Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
increased mammary gland tumor incidence J:54533
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased mammary gland tumor incidence J:70271
increased T cell derived lymphoma incidence J:81541
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:81541
Brca1tm2Arge/Brca1tm2Arge
(129-Brca1tm2Arge)
increased mammary gland tumor incidence J:69187
Brca1tm2Arge/Brca1tm2Arge
(involves: 129/Sv * C57BL/6J * MF1)
increased mammary gland tumor incidence J:69187
Brca1tm2Cxd/Brca1tm2Cxd
Pkmtm1.1Mgvh/Pkmtm1.1Mgvh
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N)
increased mammary gland tumor incidence J:205213
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
Brca1tm2Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Trp53tm1Brd/Trp53tm1Brd

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary gland tumor incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53+
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:90512
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N)
increased mammary gland tumor incidence J:94114
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
increased mammary gland ductal carcinoma incidence J:112308
increased mammary gland tumor incidence J:112308
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
increased mammary gland tumor incidence J:155810
increased T cell derived lymphoma incidence J:155810
Brca2tm1Arge/Brca2tm2Arge
Waptm1(cre)Arge/Wap+

(involves: 129S/SvEv * C57BL/6)
increased mammary adenocarcinoma incidence J:70564
Brca2tm1Brn/Brca2+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Brca2tm1Brn/Brca2tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic acinar cell carcinoma incidence J:166678
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1)
increased T cell derived lymphoma incidence J:46812
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
increased T cell derived lymphoma incidence J:44386
Brca2tm1Kamc/Brca2tm1Kamc
Trp53tm1Tyj/Trp53+

(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
increased mammary gland tumor incidence J:109193
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
increased mammary gland tumor incidence J:67445
Brca2tm2Arge/Brca2tm2Arge
Waptm1(cre)Arge/Waptm1(cre)Arge

(involves: 129S1/Sv * C57BL/6)
increased mammary adenocarcinoma incidence J:70564
Brf1tm1Arte/Brf1tm1Arte
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:285667
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
increased Harderian gland adenoma incidence J:227115
increased pituitary adenoma incidence J:227115
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn

(involves: 129 * 129P2/OlaHsd * FVB/N)
increased thyroid tumor incidence J:190366
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu

(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
increased thyroid tumor incidence J:190366
Cav1tm1Mls/Cav1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased mammary gland tumor incidence J:132472
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
increased mammary gland tumor incidence J:147439
Cav1tm1Mls/Cav1tm1Mls
Tg(MMTV-PyVT)634Mul/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased mammary gland tumor incidence J:132472
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
increased ovarian carcinoma incidence J:217742
increased thyroid adenoma incidence J:217742
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0

(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam)
increased mammary adenocarcinoma incidence J:241259
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl
Tg(MMTV-cre)1Mam/0
Tg(MMTV-PyVT)634Mul/0

(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul)
increased mammary adenocarcinoma incidence J:241259
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Lck-LMO1)11Sjk/0
Tg(Mx1-cre)1Cgn/0

(Not Specified)
increased T cell derived lymphoma incidence J:217695
Ccnd1tm1Dsn/Ccnd1tm1Dsn
Cdkn1btm1Mlf/Cdkn1btm1Mlf

(involves: 129 * C57BL/6)
increased pituitary adenoma incidence J:66707
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm4Pisc/Ccnd1tm4Pisc
Tg(MMTV-Erbb2)NK1Mul/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:156591
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Tg(Lck)4220Rmp/0

(involves: C57BL/6J * DBA/2)
increased T cell derived lymphoma incidence J:88120
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:88120
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
increased pancreatic intraepithelial neoplasia incidence J:280854
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
increased pancreatic intraepithelial neoplasia incidence J:280854
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:160931
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+

(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
increased T cell derived lymphoma incidence J:189087
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
Cdc73tm1Btt/Cdc73+
Tg(PTH-cre)4167Slib/0

(Not Specified)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
Cdc73tm1Btt/Cdc73tm1Btt
Tg(PTH-cre)4167Slib/0

(Not Specified)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:171765
increased mammary gland tumor incidence J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary gland tumor incidence J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary gland tumor incidence J:171765
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:212549
Cdh13tm1Brns/Cdh13tm1Brns
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:132759
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?

(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
increased pituitary adenoma incidence J:86101
Cdk5rap2an/Cdk5rap2an
(Not Specified)
increased ovary adenoma incidence J:15165
Cdk6tm1Phin/Cdk6+
Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:144975
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
increased Leydig cell tumor incidence J:70894
increased sebaceous gland adenoma incidence J:70894
increased T cell derived lymphoma incidence J:70894
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Tg(MMTV-vHaras)SH1Led/0

(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
increased mammary adenocarcinoma incidence J:66183
increased salivary adenocarcinoma incidence J:66183
Cdkn1btm1Ako/Cdkn1b+
KitW-v/KitW-v

(involves: 129S1/Sv * C57BL/6J)
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1b+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0

(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp)
increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
increased pituitary gland tumor incidence J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi

(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
increased pituitary adenoma incidence J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako
KitW-v/KitW-v

(involves: 129S1/Sv * C57BL/6J)
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako
Men1tm1.1Ctre/Men1+

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
increased adrenal gland tumor incidence J:120835
increased pancreas tumor incidence J:120835
increased parathyroid gland tumor incidence J:120835
increased pituitary gland tumor incidence J:120835
increased testis tumor incidence J:120835
increased thyroid tumor incidence J:120835
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
increased pituitary adenoma incidence J:33402
Cdkn1btm1Mlf/Cdkn1b+
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6 * CBA * FVB)
increased T cell derived lymphoma incidence J:88323
Cdkn1btm1Mlf/Cdkn1b+
Tg(TG-TPR/NTRK1)#Rstn/0

(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
increased pituitary adenoma incidence J:33400
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa

(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
increased prostate intraepithelial neoplasia incidence J:89571
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(TG-TPR/NTRK1)#Rstn/0

(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd

(involves: C3H * C57BL/6J * NIH)
increased T cell derived lymphoma incidence J:87536
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
increased T cell derived lymphoma incidence J:87536
Cdkn1btm2Mlf/Cdkn1btm2Mlf
Tg(Pomc1-cre)1Mlf/0

(involves: 129S4/SvJaeSor)
increased pituitary gland tumor incidence J:107588
Cdkn1btm3Mlf/Cdkn1btm3Mlf
(involves: 129S4/SvJaeSor)
increased pituitary gland tumor incidence J:107588
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:44427
Cdkn2atm1Rdp/Cdkn2a+
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
increased pancreas tumor incidence J:197052
increased pancreatic ductal adenocarcinoma incidence J:197052
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-rtTA)37Lc/0

(involves: 129/Sv * C57BL/6J * SJL)
increased prostate gland adenocarcinoma incidence J:144358
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298, J:87196
increased pancreatic ductal adenocarcinoma incidence J:116130, J:108298, J:87196
increased pancreatic intraepithelial neoplasia incidence J:87196
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:187012
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:151781
Cdkn2btm1Bbd/Cdkn2btm1Bbd
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd

(involves: 129S1/Sv * C57BL/6)
increased pituitary adenoma incidence J:63299
increased testis tumor incidence J:63299
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
increased pheochromocytoma incidence J:63299
increased pituitary adenoma incidence J:63299
increased T cell derived lymphoma incidence J:63299
increased testis tumor incidence J:63299
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Cdkn2dtm1Maro/Cdkn2dtm1Maro

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
increased pheochromocytoma incidence J:68829
increased pituitary adenoma incidence J:68829
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
increased pituitary adenoma incidence J:50053
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi)
increased mammary gland tumor incidence J:198018
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
increased adrenal gland tumor incidence J:120835
increased Leydig cell tumor incidence J:120835
increased pancreas tumor incidence J:120835
increased parathyroid gland tumor incidence J:120835
increased testis tumor incidence J:120835
increased thyroid tumor incidence J:120835
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:146176
Chek1tm1Sje/Chek1+
Tg(Wnt1)1Hev/0

(Not Specified)
increased mammary adenocarcinoma incidence J:62919
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
increased mammary adenocarcinoma incidence J:162126
increased mammary gland tumor incidence J:162126
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:162126
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:162126
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp
Tg(Mx1-cre)1Cgn/0

(Not Specified)
increased T cell derived lymphoma incidence J:199366
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:222916
increased prostate gland tumor incidence J:222916
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:171191
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:171191
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:178271
increased testicular teratoma incidence J:178271
Cop1tm2.1Vmd/Cop1+
Tg(Pbsn-cre)4Prb/0

(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
increased prostate gland adenocarcinoma incidence J:172653
increased prostate intraepithelial neoplasia incidence J:172653
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0

(B6N.Cg-Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb)
increased prostate intraepithelial neoplasia incidence J:172653
Crebbptm1Jvd/Crebbptm1Jvd
Tg(Lck-cre)548Jxm/0

(involves: 129 * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:105505
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6 * FVB)
increased T cell derived lymphoma incidence J:88323
Csf2tm1Dran/Csf2tm1Dran
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
increased ovarian carcinoma incidence J:83086
Csf2tm1Mlg/Csf2tm1Mlg
Ifngtm1Ts/Ifngtm1Ts
Il3tm1Glli/Il3tm1Glli

(B6.129S-Csf2tm1Mlg Il3tm1Glli Ifngtm1TsIfngtm1Ts)
increased pituitary adenoma incidence J:145518
Ctnnb1tm1Mmt/Ctnnb1+
Igs2tm1(CAG-Met)Zsu/Igs2+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
increased prostate gland adenocarcinoma incidence J:284956
increased prostate intraepithelial neoplasia incidence J:284956
Ctnnb1tm1Mmt/Ctnnb1+
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:143034
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Tg(CYP19A1-cre)1Jri/0

(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased ovary tumor incidence J:186144
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0

(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased ovary tumor incidence J:186144
Ctnnb1tm1Mmt/Ctnnb1+
Sox2tm1.1(cre/ERT2)Jpmb/Sox2+

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
increased pituitary gland tumor incidence J:201265
Ctnnb1tm1Mmt/Ctnnb1+
Tg(CYP19A1-cre)1Jri/0

(involves: 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased ovary tumor incidence J:186144
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Pbsn-cre)4Prb/0

(involves: 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:143034, J:284956
increased prostate intraepithelial neoplasia incidence J:143034, J:284956
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Wap-cre)11738Mam/0

(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam)
increased mammary gland tumor incidence in breeding females J:206839
Ctnnb1tm1Mmt/Ctnnb1+
Tg(Wap-cre)11738Mam/0
Tg(Wap-Hgf)402Mig/0

(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam Tg(Wap-Hgf)402Mig)
increased mammary gland tumor incidence in breeding females J:206839
increased mammary gland tumor incidence in virgin females J:206839
Ctsbtm1Jde/Ctsbtm1Jde
Ctsztm1Thre/Ctsztm1Thre
Tg(MMTV-PyVT)634Mul/0

(FVB.129P2-Ctsztm1Thre Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
increased mammary gland tumor incidence J:157541
Ctsbtm1Jde/Ctsbtm1Jde
Tg(MMTV-PyVT)634Mul/0

(FVB.129P2-Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
increased mammary gland tumor incidence J:157541
Ctsztm1Thre/Ctsztm1Thre
Tg(MMTV-PyVT)634Mul/0

(FVB.129P2-Ctsztm1Thre Tg(MMTV-PyVT)634Mul)
increased mammary gland tumor incidence J:157541
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased insulinoma incidence J:170976
increased pituitary gland tumor incidence J:170976
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased ovary tumor incidence J:170976
increased pituitary gland tumor incidence J:170976
Dcctm1Nki/Dcctm1Nki
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/?

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:181090
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
increased ovarian teratoma incidence J:102381
Dclre1atm1Rleg/Dclre1atm1Rleg
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:102381
Dcntm1Ioz/Dcn+
Trp53tm1Brd/Trp53tm1Brd

(involves: 129/Sv * Black Swiss * C57BL/6)
increased T cell derived lymphoma incidence J:53511
Dcntm1Ioz/Dcntm1Ioz
Trp53tm1Brd/Trp53tm1Brd

(involves: 129/Sv * Black Swiss * C57BL/6)
increased T cell derived lymphoma incidence J:53511
Ddr2tm1a(EUCOMM)Wtsi/Ddr2tm1a(EUCOMM)Wtsi
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6N * FVB/N)
increased mammary gland tumor incidence J:236031
Ddr2tm1b(EUCOMM)Wtsi/Ddr2tm1b(EUCOMM)Wtsi
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6N * FVB/N)
increased mammary gland tumor incidence J:236031
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi
Tg(KRT14-cre)1Amc/0
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6 * C57BL/6N * CBA * FVB/N)
increased mammary gland tumor incidence J:236031
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi
Tg(MMTV-cre)#Mam/0
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6N * FVB * FVB/N)
increased mammary gland tumor incidence J:236031
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho
Ptentm1.1Hwu/Pten+

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:212219
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
increased ovarian carcinoma incidence J:182161
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
increased ovarian carcinoma incidence J:222579
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
increased mammary adenocarcinoma incidence J:81054
increased pheochromocytoma incidence J:81054
Dmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Dmq2FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Dmtf1tm1Cjs/Dmtf1+
Krastm2Tyj/Kras+

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm2Tyj/Kras+

(involves: 129S2/SvPas * C57BL/6)
increased ovary tumor incidence J:126002
increased T cell derived lymphoma incidence J:126002
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+

(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:126002
Dnd1Ter/?
(129S1/Sv-KitW Oca2p Tyrc-ch)
increased testicular teratoma incidence J:29502
Dnd1Ter/Dnd1+
(129S1/Sv-KitW Oca2p Tyrc-ch)
increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1+
(involves: 129S1/Sv * C57BL/6)
increased testicular teratoma incidence J:7954
increased testis tumor incidence J:7954
Dnd1Ter/Dnd1+
(involves: 129P3/J)
increased testis tumor incidence J:221231
Dnd1Ter/Dnd1Ter
(129S1/Sv-KitW Oca2p Tyrc-ch)
increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1Ter
(involves: 129S1/Sv * C57BL/6)
increased testicular teratoma incidence J:7954
Dnd1Ter/Dnd1Ter
Sf1Gt(XD130)Byg/Sf1+

(involves: 129P2/OlaHsd * 129S1/SvImJ * 129T1/Sv)
increased testis tumor incidence J:164224
Dock1tm2.1Jfco/Dock1+
Tg(MMTV-Erbb2*,-cre)1Mul/0

(involves: C57BL/6 * FVB/NJ)
increased mammary adenocarcinoma incidence J:196659
increased mammary gland tumor incidence J:196659
Dock1tm2.1Jfco/Dock1tm2.1Jfco
Tg(MMTV-Erbb2*,-cre)1Mul/0

(involves: C57BL/6 * FVB/NJ)
increased mammary adenocarcinoma incidence J:196659
increased mammary gland tumor incidence J:196659
Drd2tm1Ebo/Drd2tm1Ebo
(involves: 129S2/SvPas * C57BL/6)
increased pituitary adenoma incidence J:41857
E2f1tm1Meg/E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
increased T cell derived lymphoma incidence J:33100
E2f1tm1Njd/E2f1+
Rb1tm1Tyj/Rb1+

(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
increased thyroid adenoma incidence J:47108
E2f1tm1Njd/E2f1tm1Njd
Rb1tm1Tyj/Rb1+

(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
increased pituitary gland tumor incidence J:47108
increased thyroid adenoma incidence J:47108
E2f4tm1Lees/E2f4+
Rb1tm1Tyj/Rb1+

(involves: 129S2/SvPas * C57BL/6)
increased pituitary gland tumor incidence J:81082
increased thyroid tumor incidence J:81082
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow
Eaf2tm1Zhow/Eaf2tm1Zhow
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
increased prostate intraepithelial neoplasia incidence J:288972
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow
Tg(Pbsn-cre)4Prb/0

(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
increased prostate intraepithelial neoplasia incidence J:288972
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J)
increased prostate intraepithelial neoplasia incidence J:145228
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
increased prostate intraepithelial neoplasia incidence J:288972
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1r+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv)
increased mammary gland tumor incidence J:146290
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1rtm2Arge
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv)
increased mammary gland tumor incidence J:146290
Eef1a1tm1(Kras*)Arge/Eef1a1+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv)
increased mammary adenocarcinoma incidence J:146290
increased mammary gland tumor incidence J:146290
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6)
increased T cell derived lymphoma incidence J:123870
Elac2em1Afi/Elac2em1Afi
Tg(TRAMP)8247Ng/0

(involves: C57BL/6 * C57BL/6N)
increased prostate intraepithelial neoplasia incidence J:336403
Emv30b/Emv30b
Prkdcscid/Prkdcscid

(NOD.Cg-Emv30b Prkdcscid/Dvs)
increased T cell derived lymphoma incidence J:29951
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)
increased T cell derived lymphoma incidence J:112696
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Pten+
Tg(MMTV-cre)7Mul/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133305
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)7Mul/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133305
Erbb2tm8(Erbb2)Mul/Erbb2+
Tg(MMTV-cre)7Mul/?

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:89255
Erbb3tm1.1(ERBB3)Mul/Erbb3+
Tg(MMTV-Erbb2*)NDL2-5Mul/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:189292
Erbb3tm1.1(ERBB3)Mul/Erbb3tm1.1(ERBB3)Mul
Tg(MMTV-Erbb2*)NDL2-5Mul/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:189292
Ergtm1.1Sho/Ergtm1.1Sho
Ptentm1Hwu/Ptentm1Hwu
Tmprss2tm3Sho/Tmprss2tm3Sho
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:212219
Esr1tm1Ksk/Esr1tm1Ksk
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inha+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
increased ovary tumor incidence J:84989
Esr1tm1Ksk/Esr1tm1Ksk
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inhatm1Bay

(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
increased ovary tumor incidence J:84989
increased testis tumor incidence J:84989
Esr1tm1Ksk/Esr1tm1Ksk
Inhatm1Bay/Inhatm1Bay

(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
increased ovary tumor incidence J:84989
increased testis tumor incidence J:84989
Esr1tm1Ksk/Esr1tm1Ksk
Tg(MMTV-Erbb2)NK1Mul/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
increased mammary gland tumor incidence J:76653
Esr1tm1Ksk/Esr1tm1Ksk
Tg(Wnt1)1Hev/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:54215
Esr2tm1Unc/Esr2tm1Unc
Inhatm1Bay/Inhatm1Bay

(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
increased ovary tumor incidence J:84989
increased testis tumor incidence J:84989
Ets2tm1Rgo/Ets2tm5.1Rgo
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:153747
Ets2tm3Rgo/Ets2+
Meox2tm1(cre)Sor/?
Tg(MMTV-cre)7Mul/?

(involves: 129S4/SvJaeSor * FVB/N)
increased mammary gland tumor incidence J:102368
Ets2tm3Rgo/Ets2+
Meox2tm1(cre)Sor/?
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:102368
Ets2tm3Rgo/Ets2tm3.1Rgo
Meox2tm1(cre)Sor/?
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:102368
Ets2tm3Rgo/Ets2tm3Rgo
Meox2tm1(cre)Sor/?
Tg(MMTV-cre)7Mul/?

(involves: 129S4/SvJaeSor * FVB/N)
increased mammary gland tumor incidence J:102368
Etv4tm1Hass/Etv4tm1Hass
Tg(MMTVneu)202Mul/Tg(MMTVneu)202Mul

(involves: FVB/N)
increased mammary gland tumor incidence J:87017
Etv6tm3(NTRK3)Sho/Etv6+
(involves: 129S1/Sv)
increased mammary gland tumor incidence J:130323
Etv6tm3(NTRK3)Sho/Etv6+
Tg(Wap-cre)11738Mam/0

(involves: 129S1/Sv * C57BL/6 * SJL)
increased mammary gland tumor incidence J:130323
Ewsr1tm1(ERG)Thr/Ewsr1+
Rag1tm1(cre)Thr/Rag1+

(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:98679
F2rtm1Pago/F2rtm1Pago
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul)
increased mammary adenocarcinoma incidence J:138924
F2rl1tm1Bpd/F2rl1tm1Bpd
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul)
increased mammary adenocarcinoma incidence J:138924
Fancftm1Nki/Fancftm1Nki
(involves: 129P2/OlaHsd * FVB)
increased granulosa cell tumor incidence J:180025
increased ovary tumor incidence J:180025
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified)
increased mammary gland tumor incidence J:178645
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified)
increased mammary gland tumor incidence J:178645
Fbxw7tm1Iaai/Fbxw7tm1Iaai
Tg(Lck-cre)1Cwi/0

(involves: 129/Sv * C57BL/6)
increased T cell derived lymphoma incidence J:137138
Fbxw7tm1Kei/Fbxw7tm1Kei
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Lck-cre)1Cwi/?

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:128523
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
increased T cell derived lymphoma incidence J:244082
Fen1tm2.1Bhsh/Fen1tm2.1Bhsh
(involves: 129S1/Sv)
increased thymus tumor incidence J:218627
Fgfr4tm1Axul/Fgfr4+
Tg(WapTgfa)215Bri/0

(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
increased mammary adenocarcinoma incidence J:156750
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0

(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
increased mammary adenocarcinoma incidence J:156750
Fgfr4tm1Axul/Fgfr4tm1Axul
Tg(WapTgfa)215Bri/0

(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
increased mammary adenocarcinoma incidence J:156750
Flot2tm1Mak/Flot2tm1Mak
Tg(MMTV-PyVT)634Mul/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:203238
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased granulosa cell tumor incidence J:232961
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0

(involves: 129S4/SvJae * 129S6/SvEvTac)
increased granulosa cell tumor incidence J:232961
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Tg(CYP19A1-cre)1Jri/0

(involves: 129S6/SvEvTac)
increased granulosa cell tumor incidence J:232961
Foxo1tm1Rdp/Foxo1tm1Rdp
Foxo3tm1Rdp/Foxo3tm1Rdp
Foxo4tm1Rdp/Foxo4tm1Rdp
Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
increased T cell derived lymphoma incidence J:118179
Foxo3mommeR1/Foxo3mommeR1
Tg(HBA1-GFP)1Ew/Tg(HBA1-GFP)1Ew

(FVB/NJ-Foxo3mommeR1 Tg(HBA1-Gfp)1Ew)
increased ovarian teratoma incidence J:170710
Foxo3tm1.1Rdp/Foxo3+
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp

(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
increased Harderian gland tumor incidence J:118179
increased ovary tumor incidence J:118179
increased pituitary adenoma incidence J:118179
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
increased ovary tumor incidence J:118179
increased prolactinoma incidence J:118179
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
Foxo4tm1.1Rdp/Foxo4tm1.1Rdp

(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
increased Harderian gland tumor incidence J:118179
increased ovarian teratoma incidence J:118179
increased ovary tumor incidence J:118179
increased pituitary adenoma incidence J:118179
Fshrtm1Saco/Fshr+
(involves: 129)
increased ovary tumor incidence J:140008
Fshrtm1Saco/Fshrtm1Saco
(involves: 129)
increased ovarian carcinoma incidence J:70933
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:137456
increased mammary gland tumor incidence J:137456
increased testis tumor incidence J:137456
Gcgrtm1Jcp/Gcgrtm1Jcp
(DBA/1LacJ-Gcgrtm1Jcp)
increased glucagonoma incidence J:176507
increased pancreas tumor incidence J:176507
Gct1SJL/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
increased granulosa cell tumor incidence J:49710
Gct1SWR/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
increased granulosa cell tumor incidence J:49710
Gct4SJL/Bm/?
(involves: SJL * SWR)
increased granulosa cell tumor incidence J:49710
Gct4SJL/Bm/Gct4SJL/Bm
(involves: SJL * SWR)
increased granulosa cell tumor incidence J:87114
Gct4SJL/Bm/Gct4SJL/Bm
Gct6SJL/Gct6SJL

(involves: CAST/Ei * SJL * SWR)
increased granulosa cell tumor incidence J:87114
Gct5SWXJ9/BmJ/Gct5SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
increased granulosa cell tumor incidence J:96787
Gct7SWXJ9/BmJ/Gct7SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
increased granulosa cell tumor incidence J:96787
Gct8SWXJ9/BmJ/Gct8SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
increased granulosa cell tumor incidence J:96787
Gct9SWXJ9/BmJ/Gct9SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
increased granulosa cell tumor incidence J:96787
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
increased salivary adenocarcinoma incidence J:197352
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
increased mammary adenocarcinoma incidence J:193993
increased salivary gland tumor incidence J:193993
Grb2tm1Paw/Grb2+
Ptentm1Mak/Pten+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
increased adrenal gland tumor incidence J:93530
Grb2tm1Paw/Grb2+
Ptentm2Mak/Ptentm2Mak
Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:93530
Grb2tm1Paw/Grb2+
Tg(MMTV-PyVT)634Mul/?

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary adenocarcinoma incidence J:51424
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+
Tg(Osr1-cre)4Mrt/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
increased prostate gland adenocarcinoma incidence J:234601
increased prostate intraepithelial neoplasia incidence J:234601
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu
Tg(Osr1-cre)4Mrt/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
increased prostate gland adenocarcinoma incidence J:234601
increased prostate intraepithelial neoplasia incidence J:234601
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
increased prostate gland adenocarcinoma incidence J:184533
increased prostate intraepithelial neoplasia incidence J:184533
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0

(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
increased pituitary gland tumor incidence J:187257
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0

(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
increased pituitary gland tumor incidence J:187257
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Gfap-cre)2Brn/0

(either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N))
increased mammary gland tumor incidence J:187257
increased pituitary gland tumor incidence J:187257
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
increased prostate intraepithelial neoplasia incidence J:184533
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1+
Tg(Pbsn-cre)4Prb/0

(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:307910
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:307910
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0

(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:307910
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(MMTV-cre)7Mul/0

(involves: BALB/c * FVB/N)
increased mammary adenocarcinoma incidence J:173655
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(Wap-cre)1Gsc/0

(involves: BALB/c * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:173655
increased mammary gland tumor incidence J:173655
Gt(ROSA)26Sortm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:231906
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3+
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:179414
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:179414
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
increased prostate gland tumor incidence J:130367
increased prostate intraepithelial neoplasia incidence J:130367
increased T cell derived lymphoma incidence J:130367
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:280854
increased pancreatic intraepithelial neoplasia incidence J:280854
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1.1Hwu/Pten+

(involves: 129S4/SvJae * C57BL/6NTac)
increased thyroid adenoma incidence J:170965
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:170965
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:160931
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?

(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
increased prostate gland adenocarcinoma incidence J:238768
increased prostate intraepithelial neoplasia incidence J:238768
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0

(involves: 129S4/SvJae * 129S4/SvJaeSor)
increased pancreatic intraepithelial neoplasia incidence J:142188
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0

(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA)
increased pancreatic intraepithelial neoplasia incidence J:142188
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+
Tg(Lck-cre)548Jxm/0

(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm)
increased T cell derived lymphoma incidence J:185287
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)1Mam/0

(involves: 129S6/SvEvTac * FVB/N)
increased mammary gland tumor incidence J:170898
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0

(involves: 129S6/SvEvTac)
increased mammary adenocarcinoma incidence J:170898
increased mammary gland tumor incidence J:170898
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
increased mammary adenocarcinoma incidence J:170898
increased mammary gland tumor incidence J:170898
increased T cell derived lymphoma incidence J:170898
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
increased mammary gland tumor incidence J:170898
increased T cell derived lymphoma incidence J:170898
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
increased pancreas tumor incidence J:184378
increased pancreatic intraepithelial neoplasia incidence J:184378
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:184378
increased pancreatic intraepithelial neoplasia incidence J:184378
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:186194
increased pancreatic intraepithelial neoplasia incidence J:186194
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:186194
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:186194
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6057Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6113Njen/0

(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:102234
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc3)12740Njen/0

(involves: C3H * C57BL/6J)
increased pheochromocytoma incidence J:153656
increased T cell derived lymphoma incidence J:153656
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Pten+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:239660
increased prostate intraepithelial neoplasia incidence J:239660
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:239660
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:200002
increased prostate intraepithelial neoplasia incidence J:200002
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J)
increased pancreatic ductal adenocarcinoma incidence J:140423
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129S6/SvEvTac * C57BL/6J)
increased pancreatic ductal adenocarcinoma incidence J:140423
increased pancreatic intraepithelial neoplasia incidence J:140423
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:226601
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:226601
increased pancreatic ductal adenocarcinoma incidence J:226601
increased pancreatic intraepithelial neoplasia incidence J:226601
increased sebaceous gland tumor incidence J:226601
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:170965
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse
Tg(Wap-cre)11738Mam/0

(involves: 129 * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:169403
increased pituitary gland tumor incidence J:169403
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129S6/SvEvTac)
increased pancreatic ductal adenocarcinoma incidence J:197054
increased pancreatic intraepithelial neoplasia incidence J:197054
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Tg(Cela1-cre/ERT)1Dam/0

(involves: 129S6/SvEvTac)
increased pancreatic intraepithelial neoplasia incidence J:197054
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153656
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:245611
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+

(involves: 129 * C57BL/6NCrl * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:245611
increased pancreatic intraepithelial neoplasia incidence J:245611
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+

(involves: 129 * C57BL/6NCrl * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:245611
increased pancreatic intraepithelial neoplasia incidence J:245611
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0

(involves: C57BL/6 * CD-1 * SJL)
increased thymus tumor incidence J:263520
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
H2u/H2u
Tg(TCRA)B1Jg/0

(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J)
increased T cell derived lymphoma incidence J:92992
H2u/H2u
Tg(TCRA)B1Jg/0
Tg(TCRB)C14Jg/0

(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)
increased T cell derived lymphoma incidence J:92992
H2axtm1Fwa/H2ax+
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:84879
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:84879
H2axtm1Fwa/H2axtm1Fwa
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:84879
Hace1tm1Pngr/Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:125183
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc
Hdac2tm1.1Shmc/Hdac2tm1.1Shmc
Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:194769
HelqGt(RRF112)Byg/Helq+
(involves: 129P2/OlaHsd * C57BL/6)
increased Harderian gland tumor incidence J:206104
increased pituitary adenoma incidence J:206104
HelqGt(RRF112)Byg/HelqGt(RRF112)Byg
(involves: 129P2/OlaHsd * C57BL/6)
increased gland tumor incidence J:206104
increased granulosa cell tumor incidence J:206104
increased Harderian gland tumor incidence J:206104
increased mammary gland tumor incidence J:206104
increased ovary tumor incidence J:206104
increased pituitary adenoma incidence J:206104
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
increased pancreatic islet cell carcinoma incidence J:81448
Hip1tm4Tsr/Hip1+
Tg(Mx1-cre)1Cgn/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:151974
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ)
increased pheochromocytoma incidence J:100773
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:285667
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep)
increased mammary adenocarcinoma incidence J:152682
increased mammary gland tumor incidence J:152682
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y
Ptentm2Mak/Ptentm2Mak

(involves: 129P2/OlaHsd * C57BL/6)
increased prostate gland adenocarcinoma incidence J:144357
increased prostate intraepithelial neoplasia incidence J:144357
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep)
increased mammary adenocarcinoma incidence J:152682
increased mammary gland tumor incidence J:152682
Hrastm1Jaf/Hrastm1Jaf
Nf2tm2Gth/Nf2tm2Gth
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
increased thyroid tumor incidence J:231492
Hrastm1Jaf/Hrastm1Jaf
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0

(involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr)
increased thyroid tumor incidence J:231492
Hrastm1Jaf/Hrastm1Jaf
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
increased thyroid tumor incidence J:231492
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:137729
Hspa5tm1Alee/Hspa5+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?

(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:142106
increased prostate intraepithelial neoplasia incidence J:142106
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J)
increased ovary tumor incidence J:87066
Icostm1Flv/Icostm1Flv
Rc3h1san/Rc3h1+

(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)
increased T cell derived lymphoma incidence J:189087
Id1tm1Zhu/Id1tm1Zhu
Tcf3tm1Wein/Tcf3tm1Wein

(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
increased T cell derived lymphoma incidence J:44278
Id2tm1Yyk/Id2+
Tg(Wnt1)1Hev/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
increased mammary gland tumor incidence J:96305
Id2tm1Yyk/Id2tm1Yyk
Tg(Wnt1)1Hev/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
increased mammary gland tumor incidence J:96305
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
increased T cell derived lymphoma incidence J:77491
Igh-Vtm1(Igh-Vx24)Hmb/Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6)
increased T cell derived lymphoma incidence J:54380
Ightm1(PAX5)Mbu/Igh+
(B6.Cg-Ightm1(PAX5)Mbu)
increased T cell derived lymphoma incidence J:118111
Ightm1(PAX5)Mbu/Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu)
increased T cell derived lymphoma incidence J:118111
Igs2tm1(CAG-Met)Zsu/Igs2+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129 * C57BL/6 * DBA/2 * FVB/N)
increased prostate gland adenocarcinoma incidence J:268934
increased prostate gland tumor incidence J:268934
increased prostate intraepithelial neoplasia incidence J:268934
Igs2tm1(CAG-Met)Zsu/Igs2+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
increased prostate intraepithelial neoplasia incidence J:268934
Ikzf1plstc/Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc)
increased T cell derived lymphoma incidence J:84569
Ikzf1tm1(Pax5)Mbu/Ikzf1+
Tg(Lck-cre)1Cwi/0

(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:118111
Ikzf1tm1.1(Pax5)Mbu/Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:118111
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu
Il7rtm1.1(icre)Hrr/Il7r+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:209928
Ikzf1tm3Kge/Ikzf1tm3Kge
Tg(CD2-icre)4Kio/?

(involves: C57BL/10 * CBA/Ca)
increased T cell derived lymphoma incidence J:209927
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
increased Harderian gland adenoma incidence J:167311
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
increased adrenal gland tumor incidence J:125349, J:20450
increased ovary tumor incidence J:125349, J:3315
increased testis tumor incidence J:125349
Inhatm1Bay/Inhatm1Bay
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased ovary tumor incidence J:84989
increased testis tumor incidence J:84989
Inhatm1Bay/Inhatm1Bay
Smad3tm1Par/Smad3+

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
increased adrenal gland tumor incidence J:125349
increased ovary tumor incidence J:125349
Inhatm1Bay/Inhatm1Bay
Smad3tm1Par/Smad3tm1Par

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
increased ovary tumor incidence J:125349
Ino80tm1.1Schg/Ino80+
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:221224
Inpp5jtm1.1Cmit/Inpp5jtm1.1Cmit
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6)
increased mammary gland tumor incidence J:224914
Kdm5atm1.1Kael/Kdm5a+
Rb1tm1Tyj/Rb1+

(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
increased pituitary gland tumor incidence J:175625
increased thyroid tumor incidence J:175625
Kdm5atm1.1Kael/Kdm5atm1.1Kael
Rb1tm1Tyj/Rb1+

(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
increased pituitary gland tumor incidence J:175625
increased thyroid tumor incidence J:175625
Kdm5atm1Kael/Kdm5atm1Kael
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
increased insulinoma incidence J:175625
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
increased ovary tumor incidence J:236161
KitlSl-J/Kitl+
(involves: 129)
increased testicular teratoma incidence J:50508
KitlSl/Kitl+
(involves: 129/Sv * C3H)
increased testicular teratoma incidence J:50508
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(TRAMP)8247Ng/?

(involves: C57BL/6 * CD-1)
increased prostate gland tumor incidence J:134509
Kmt2atm1Thr/Kmt2a+
Mllt3tm2Thr/Mllt3+
Tg(Lck-cre)1Thr/?

(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:100794
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:276349
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:143034
increased prostate intraepithelial neoplasia incidence J:143034
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:119988
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:119988
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:68981
Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:164198
Krastm3Tyj/Krastm3Tyj
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:237900
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Tuv/0
TgTn(sb-T2/Onc)#Dla/0

(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
increased pancreas tumor incidence J:186717
increased pancreatic ductal adenocarcinoma incidence J:186717
increased pancreatic intraepithelial neoplasia incidence J:186717
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
Ptentm2Mak/Ptentm2Mak

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
increased pancreatic intraepithelial neoplasia incidence J:254370
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:184935
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * BALB/c * C57BL/6)
increased pancreas tumor incidence J:164210
increased pancreatic ductal adenocarcinoma incidence J:164210
increased pancreatic intraepithelial neoplasia incidence J:164210
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae)
increased ovary tumor incidence J:161953
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:184935
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:164210
increased pancreatic intraepithelial neoplasia incidence J:164210
Krastm4Tyj/Kras+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0

(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp)
increased thyroid carcinoma incidence J:147732
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic ductal adenocarcinoma incidence J:116130, J:87973
increased pancreatic intraepithelial neoplasia incidence J:262746
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
increased pancreatic intraepithelial neoplasia incidence J:116129
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw)
increased pancreas tumor incidence J:138959
increased pancreatic ductal adenocarcinoma incidence J:138959
increased pancreatic intraepithelial neoplasia incidence J:138959
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MUC1)79.24Gend/0

(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend)
increased pancreas tumor incidence J:138959, J:234412
increased pancreatic ductal adenocarcinoma incidence J:138959
increased pancreatic intraepithelial neoplasia incidence J:138959, J:234412
Krastm4Tyj/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased pancreatic ductal adenocarcinoma incidence J:197054
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
Tg(Pbsn-cre)20Fwan/0

(involves: 129S4/SvJae * FVB/NCrl)
increased prostate gland adenocarcinoma incidence J:178461
increased prostate intraepithelial neoplasia incidence J:178461
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0

(involves: 129S4/SvJae * FVB/NCrl)
increased prostate gland adenocarcinoma incidence J:178461
increased prostate intraepithelial neoplasia incidence J:178461
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Krastm4Tyj/Kras+
Tg(CAG-Bgeo,-tsA58T)T26Ichi/0
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:214846
increased pancreatic intraepithelial neoplasia incidence J:214846
Krastm4Tyj/Kras+
Tg(Cela1-cre/ERT)1Dam/0

(involves: 129S4/SvJae)
increased pancreas tumor incidence J:197054
Krastm4Tyj/Kras+
Tg(Erbb2*)#Maed/0
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
increased pancreatic intraepithelial neoplasia incidence J:262746
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
increased lymphoblastic lymphoma incidence J:88163
Krastm4Tyj/Kras+
Tg(Pbsn-cre)20Fwan/0

(involves: 129S4/SvJae * FVB/NCrl)
increased prostate intraepithelial neoplasia incidence J:178461
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/?

(involves: 129S4/SvJae * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:87973
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic intraepithelial neoplasia incidence J:276349, J:214846, J:98936
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Gev/Trp53tm1Gev

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:220300
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:276349
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Y

(involves: 129S4/SvJae * FVB/N)
increased pancreas tumor incidence J:186717
increased pancreatic intraepithelial neoplasia incidence J:186717
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Usp9x+

(involves: 129S4/SvJae * FVB/N)
increased pancreas tumor incidence J:186717
increased pancreatic intraepithelial neoplasia incidence J:186717
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:116130, J:164210
increased pancreatic intraepithelial neoplasia incidence J:87196, J:164210
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:116129
increased pancreatic ductal adenocarcinoma incidence J:116129
increased pancreatic intraepithelial neoplasia incidence J:116129
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:116129
increased pancreatic ductal adenocarcinoma incidence J:116129
increased pancreatic intraepithelial neoplasia incidence J:116129
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased pancreatic ductal adenocarcinoma incidence J:197054
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:98936
increased pancreatic intraepithelial neoplasia incidence J:98936
increased T cell derived lymphoma incidence J:98936
Krastm4Tyj/Krastm4Tyj
Bhlha15tm3(cre/ERT2)Skz/Bhlha15+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic intraepithelial neoplasia incidence J:142189
Krastm4Tyj/Krastm4Tyj
Ptf1atm1(cre)Hnak/Ptf1a+

(involves: 129S4/SvJae)
increased pancreatic intraepithelial neoplasia incidence J:162125
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT2)1Stof/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased pancreatic intraepithelial neoplasia incidence J:142189
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0

(involves: 129S4/SvJae)
increased pancreatic intraepithelial neoplasia incidence J:142188
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased pancreatic intraepithelial neoplasia incidence J:151781
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic intraepithelial neoplasia incidence J:142188
Krastm4Tyj/Krastm4Tyj
Trim33tm1Los/Trim33tm1Los
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:151781
increased pancreatic intraepithelial neoplasia incidence J:151781
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53+

(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
increased pancreatic ductal adenocarcinoma incidence J:248550
increased pancreatic intraepithelial neoplasia incidence J:248550
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53tm1.1Dgk

(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
increased pancreatic ductal adenocarcinoma incidence J:248550
increased pancreatic intraepithelial neoplasia incidence J:248550
Krt14tm1.1(cre)Wbm/Krt14+
Tg(KRT14-Snai1)1Efu/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * CD-1)
increased sebaceous gland tumor incidence J:229072
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J)
increased ovary tumor incidence J:52536
Ldahtm1Mrtn/Ldahtm1Mrtn
(CBACa.129S4(B6)-Ldahtm1Mrtn)
increased prostate intraepithelial neoplasia incidence J:101977
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:157574
ll/ll
X/Yaa

(BXSB/MpJScr-ll)
increased T cell derived lymphoma incidence J:10973
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:263530
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J)
increased mammary gland tumor incidence J:119989
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J)
increased mammary gland tumor incidence J:119989
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(MMTV-cre)4Mam/0
Tg(MMTV-Erbb2)1Pv/0

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N)
increased mammary adenocarcinoma incidence J:170904
increased mammary gland tumor incidence J:170904
Map3k1tm1Glj/Map3k1tm1Glj
Tg(MMTV-PyVT)634Mul/0

(involves: 129S/SvEv * FVB/N)
increased mammary gland tumor incidence J:112298
MclrRF/J/MclrSWR/J
(involves: RF/J * SWR/J)
increased T cell derived lymphoma incidence J:9614
MclrSWR/J/MclrSWR/J
(involves: RF/J * SWR/J)
increased T cell derived lymphoma incidence J:9614
Mcm2Gt(AB0178)Wtsi/Mcm2+
Mcm4chaos3/Mcm4chaos3

(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
increased T cell derived lymphoma incidence J:165667
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4chaos3

(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
increased mammary gland tumor incidence J:165667
Mcm3Gt(RRR002)Byg/Mcm3+
Mcm4chaos3/Mcm4Gt(RRE056)Byg

(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
increased mammary gland tumor incidence J:165667
Mcm4chaos3/Mcm4chaos3
(involves: C57BL/6J)
increased mammary gland tumor incidence J:165667
increased T cell derived lymphoma incidence J:165667
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3)
increased mammary adenocarcinoma incidence J:117494
increased mammary gland tumor incidence J:117494
Mcm8tm1.1Geno/Mcm8tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
increased ovary adenoma incidence J:187623
increased ovary tumor incidence J:187623
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ)
increased ovary tumor incidence J:177420
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
increased ovary tumor incidence J:177420
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
increased ovary tumor incidence J:177420
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:189297
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo)
increased mammary adenocarcinoma incidence J:164201
Mdm2tm3.1Glo/Mdm2tm3.1Glo
Trp53tm3.1Glo/Trp53+

(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo)
increased mammary adenocarcinoma incidence J:164201
Mdm2tm3.1Snj/Mdm2tm3.1Snj
(involves: 129S4/SvJae * C57BL/6)
increased salivary gland tumor incidence J:189297
Men1tm1.1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
increased pancreas tumor incidence J:67128
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * FVB/N)
increased adrenal gland tumor incidence J:133299
increased pancreatic islet cell adenoma incidence J:133299
increased parathyroid adenoma incidence J:133299
increased pheochromocytoma incidence J:133299
increased pituitary adenohypophysis tumor incidence J:133299
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6)
increased adrenal gland tumor incidence J:120835
increased gland tumor incidence J:120835
increased pancreas tumor incidence J:120835
increased parathyroid gland tumor incidence J:120835
increased pituitary gland tumor incidence J:120835
increased testis tumor incidence J:120835
increased thyroid tumor incidence J:120835
Men1tm1.1Ctre/Men1+
Rb1tm1Tyj/Rb1+

(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N)
increased adrenal gland tumor incidence J:133299
increased pancreas tumor incidence J:133299
increased parathyroid gland tumor incidence J:133299
increased pheochromocytoma incidence J:133299
increased pituitary adenohypophysis tumor incidence J:133299
increased pituitary melanotroph tumor incidence J:133299
increased thyroid C-cell carcinoma incidence J:133299
Men1tm1.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
increased adrenal gland adenoma incidence J:116086
increased glucagonoma incidence J:116086
increased insulinoma incidence J:116086
increased Leydig cell tumor incidence J:116086
increased ovary tumor incidence J:116086
increased pancreas adenoma incidence J:116086
increased parathyroid adenoma incidence J:116086
increased pituitary adenoma incidence J:116086
increased prolactinoma incidence J:116086
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)1Heed/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1+
Tg(Ins2-cre)25Mgn/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)1Heed/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Ctre/Men1tm1.2Ctre
Tg(Ins2-cre)25Mgn/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased insulinoma incidence J:85042
Men1tm1.2Zqw/Men1tm1.2Zqw
Tg(Ins2-cre)23Herr/0

(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
increased insulinoma incidence J:85133
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
increased adrenal gland tumor incidence J:67128
increased pancreas tumor incidence J:67128
increased parathyroid adenoma incidence J:67128
increased pheochromocytoma incidence J:67128
increased pituitary adenoma incidence J:67128
increased prolactinoma incidence J:67128
increased thyroid adenoma incidence J:67128
Men1tm1Ctre/Men1tm1Ctre
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
increased insulinoma incidence J:146440
Men1tm1Gfk/Men1tm1Gfk
Tg(Ins2-cre)25Mgn/0

(involves: 129T2/SvEms * C57BL/6 * C57BL/6J * DBA)
increased insulinoma incidence J:89898
increased pancreas tumor incidence J:89898
increased prolactinoma incidence J:89898
Men1tm1Rvt/Men1+
(involves: 129 * C57BL/6)
increased adrenal cortical tumor incidence J:191261
increased ovary tumor incidence J:191261
increased pancreatic islet cell adenoma incidence J:191261
increased parathyroid adenoma incidence J:191261
increased parathyroid gland tumor incidence J:191261
increased pituitary adenohypophysis tumor incidence J:191261
increased pituitary gland tumor incidence J:191261
increased testis tumor incidence J:191261
increased thyroid tumor incidence J:191261
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd)
increased adrenal cortical tumor incidence J:85302
increased adrenal gland adenoma incidence J:85302
increased adrenal gland tumor incidence J:85302
increased adrenocortical adenoma incidence J:85302
increased gland tumor incidence J:85302
increased glucagonoma incidence J:85302
increased insulinoma incidence J:85302
increased Leydig cell tumor incidence J:85302
increased mammary gland tumor incidence J:85302
increased ovary tumor incidence J:85302
increased pancreas tumor incidence J:85302
increased pancreatic islet cell adenoma incidence J:85302
increased pancreatic islet cell carcinoma incidence J:85302
increased parathyroid adenoma incidence J:85302
increased pituitary adenohypophysis tumor incidence J:85302
increased prolactinoma incidence J:85302
increased testis tumor incidence J:85302
increased thyroid carcinoma incidence J:85302
increased thyroid tumor incidence J:85302
Men1tm2.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
increased insulinoma incidence J:116086
increased Leydig cell tumor incidence J:116086
increased ovary tumor incidence J:116086
increased pancreas adenoma incidence J:116086
increased parathyroid adenoma incidence J:116086
increased pituitary adenoma incidence J:116086
Men1tm2.1Mmey/Men1tm2.1Mmey
Tg(Ins2-cre)23Herr/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
increased insulinoma incidence J:175625
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N)
increased mammary adenocarcinoma incidence J:151890
increased mammary gland tumor incidence J:151890
Mgmttm1Mse/Mgmttm1Mse
(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
Mgmttm1Mse/Mgmttm1Mse
Mlh1tm1Mse/Mlh1tm1Mse

(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
increased T cell derived lymphoma incidence J:173230
Mir216aem1Uf/Mir216aem1Uf
Tg(Ela-KRAS*G12D)9Eps/0

(involves: C57BL/6N * FVB)
increased pancreas tumor incidence J:278847
Mir216aem2Uf/Mir216aem2Uf
Tg(Ela-KRAS*G12D)9Eps/0

(involves: C57BL/6N * FVB)
increased pancreas tumor incidence J:278847
Mir216bem1Uf/Mir216bem1Uf
Tg(Ela-KRAS*G12D)9Eps/0

(involves: C57BL/6N * FVB)
increased pancreas tumor incidence J:278847
Mir217em1Uf/Mir217em1Uf
Tg(Ela-KRAS*G12D)9Eps/0

(involves: C57BL/6N * FVB)
increased pancreas tumor incidence J:278847
Mir217em2Uf/Mir217em2Uf
Tg(Ela-KRAS*G12D)9Eps/0

(involves: C57BL/6N * FVB)
increased pancreas tumor incidence J:278847
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(ARR2/Pbsn-MYC)7Key/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J)
increased prostate gland adenocarcinoma incidence J:223213
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
increased T cell derived lymphoma incidence J:47642
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:53451
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:53451
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
increased T cell derived lymphoma incidence J:153684
Mmp7tm1Lmm/Mmp7tm1Lmm
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:140033
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(MMTV-PyVT)634Mul/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:140033
Mmp9tm1Tvu/Mmp9tm1Tvu
Tg(MMTV-PyVT)634Mul/0

(involves: 129S6/SvEvTac * FVB/N)
increased mammary gland tumor incidence J:140033
Mmp11tm1Mrio/Mmp11tm1Mrio
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB)
increased mammary gland tumor incidence J:86074
Mnttm1Awb/Mnttm1.1Awb
Tg(MMTV-cre)4Mam/?

(involves: 129S6/SvEvTac * FVB/N)
increased mammary adenocarcinoma incidence J:110115
Mnttm1Phu/Mnttm1Phu
Tg(MMTV-cre)4Mam/?

(involves: FVB)
increased mammary adenocarcinoma incidence J:85481
Mob1atm1.2Asuz/Mob1a+
Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi

(involves: 129P2/OlaHsd * C57BL/6)
increased mammary gland tumor incidence J:193981
increased salivary gland tumor incidence J:193981
Mob1atm1.2Asuz/Mob1atm1.2Asuz
Mob1bGt(CC0690)Wtsi/Mob1b+

(involves: 129P2/OlaHsd * C57BL/6)
increased mammary gland tumor incidence J:193981
increased salivary gland tumor incidence J:193981
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd)
increased mammary gland tumor incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
increased T cell derived lymphoma incidence J:27469
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:45433
increased T cell derived lymphoma incidence J:45433
Msh2tm1Htr/Msh2tm1Htr
Tap1tm1Hpl/Tap1tm1Hpl

(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:45433
Msh2tm1Mak/Msh2+
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld

(involves: 129 * C57BL/6J)
increased ovary tumor incidence J:89742
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
increased lymphoblastic lymphoma incidence J:79016
Msh2tm1Whl/Msh2tm1Whl
Rb1tm1Brd/Rb1+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
increased lymphoblastic lymphoma incidence J:79016
increased pheochromocytoma incidence J:79016
increased pituitary adenohypophysis tumor incidence J:79016
increased pituitary melanotroph tumor incidence J:79016
increased thyroid C-cell carcinoma incidence J:79016
Msh5tm1Htr/Msh5tm1Htr
(involves: 129P2/OlaHsd * FVB)
increased granulosa cell tumor incidence J:180025
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
increased prostate gland adenocarcinoma incidence J:96884
increased prostate intraepithelial neoplasia incidence J:96884
Mtes1AKR/J/?
(involves: AKR/J * DBA/2J)
increased mammary gland tumor incidence J:73358
Mtf1Thyls-BALB/c/Mtf1Thyls-BALB/c
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:71358
Mtf1Thyls-BALB/c/Mtf1Thyls-MSM
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:85264, J:71358
Mtv2a/Mtv2a
(DDD.GR-Mtv2a)
increased mammary adenocarcinoma incidence J:109201
Muc1tm1Gend/Muc1tm1Gend
Tg(WapTgfa)215Bri/0

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased mammary gland tumor incidence J:123146
Mutyhtm1Jhmi/Mutyhtm1Jhmi
Ogg1tm1Tld/Ogg1tm1Tld

(involves: 129 * C57BL/6J)
increased ovary tumor incidence J:89742
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:195140
Nbnem7Jpt/Nbntm2Zqw
Tg(VAV1-cre)1Graf/0

(involves: 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:277750
Nbntm1Xu/Nbntm1Xu
(Not Specified)
increased T cell derived lymphoma incidence J:75272
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6)
increased Leydig cell tumor incidence J:86563
increased mammary adenocarcinoma incidence J:86563
increased prostate intraepithelial neoplasia incidence J:86563
increased T cell derived lymphoma incidence J:86563
increased thyroid adenoma incidence J:86563
Ncoa3tm1Jxu/Ncoa3+
Tg(MMTV-vHaras)SH1Led/0

(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
increased mammary adenocarcinoma incidence J:88789
increased mammary gland tumor incidence J:88789
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
increased pancreas tumor incidence J:210264
increased T cell derived lymphoma incidence J:210264
increased testis tumor incidence J:210264
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
increased T cell derived lymphoma incidence J:210264
Nf1tm1Par/Nf1tm1Par
H2az2Tg(Wnt1-cre)11Rth/H2az2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased pheochromocytoma incidence J:80323
Nf1tm1Par/Nf1tm1Par
Tg(Mpz-cre)94Imeg/0

(involves: 129S1/Sv * 129X1/SvJ)
increased pheochromocytoma incidence J:80323
Nf1tm1Par/Nf1tm1Par
Tg(Pax3-cre)1Joe/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased pheochromocytoma incidence J:80323
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6)
increased adrenal gland tumor incidence J:18542
increased pheochromocytoma incidence J:18542
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
increased fibroadenoma incidence J:63264
Nf2tm2Gth/Nf2+
Tg(Mpz-cre)#Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased fibroadenoma incidence J:63264
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+

(involves: 129P2/OlaHsd * FVB/N)
increased pituitary adenoma incidence J:173718
Nf2tm2Gth/Nf2tm2Gth
Tg(Mpz-cre)3Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased fibroadenoma incidence J:63264
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:132943
Nhej1tm1Fwa/Nhej1tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129)
increased T cell derived lymphoma incidence J:138774
Nkx3-1tm1Mms/Nkx3-1+
Ptentm1Rps/Pten+

(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
increased prostate gland tumor incidence J:75085
increased prostate intraepithelial neoplasia incidence J:75085
Nkx3-1tm1Mms/Nkx3-1tm1Mms
(involves: 129S1/Sv)
increased prostate intraepithelial neoplasia incidence J:131932
Nkx3-1tm1Mms/Nkx3-1tm1Mms
Ptentm1Rps/Pten+

(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
increased prostate gland tumor incidence J:75085
increased prostate intraepithelial neoplasia incidence J:75085
Nkx3-1tm1Saa/Nkx3-1tm1Saa
Tg(KLK3-cre)13Saa/?

(involves: C57BL/6)
increased prostate intraepithelial neoplasia incidence J:74350
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased prostate gland adenocarcinoma incidence J:153425
increased prostate intraepithelial neoplasia incidence J:191327, J:153425
Nmitm1.1Geno/Nmitm1.1Geno
Tg(KRT14-cre)1Amc/0
Tg(MMTVneu)202Mul/0

(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
increased mammary adenocarcinoma incidence J:261035
Nr0b1tm1.1Lja/Y
(involves: 129S1/Sv * 129X1/SvJ)
increased testis tumor incidence J:71710
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6)
increased pancreas tumor incidence J:227197
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)1Amc/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
increased mammary gland tumor incidence J:197442
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)1Amc/0

(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
increased mammary gland tumor incidence J:197442
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J)
increased glucagonoma incidence J:236511
increased pancreas tumor incidence J:236905
increased pancreatic ductal adenocarcinoma incidence J:236905
increased pancreatic islet cell adenoma incidence J:236905
Pcsk6tm1Rob/Pcsk6tm1Rob
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased ovary tumor incidence J:180839
Per2tm1Ccl/Per2tm1Ccl
(involves: 129 * C57BL/6)
increased salivary gland tumor incidence J:79456
Pgct1129S1/SvImJ/?
(involves: 129S1/SvImJ * C57BL/6J)
increased testis tumor incidence J:63413
Pik3catm1.1Waph/Pik3ca+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6)
increased granulosa cell tumor incidence J:184382
increased ovary tumor incidence J:184382
Pik3catm1.1Waph/Pik3ca+
Tg(MMTV-cre)#Mam/0

(involves: 129S1/Sv * C57BL/6 * FVB)
increased fibroadenoma incidence J:187299
increased mammary adenoacanthoma incidence J:187299
increased mammary gland tumor incidence J:187299
Pik3catm1Gne/Pik3ca+
Tg(MMTV-cre)1Mam/0

(involves: C57BL/6N * FVB/N)
increased mammary gland tumor incidence J:193377
Pik3catm1Jjz/Pik3catm1Jjz
Tg(Pbsn-cre)4Prb/0

(involves: 129 * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:138565
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased Harderian gland adenoma incidence J:171997
increased mammary gland tumor incidence J:171997
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53+

(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:171997
increased ovary tumor incidence J:171997
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:171997
Plbcq6M16i/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Pldmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Pldmq3FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Pldmq4FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Pldmq5FVB/NJ/?
(involves: FVB/NJ * M16i)
increased mammary gland tumor incidence J:136011
Plgtm1Jld/Plgtm1Jld
Tg(MMTV-PyVT)634Mul/0

(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
increased mammary adenocarcinoma incidence J:48285
Pmltm1.1Ews/Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:262172
Pmltm1Ppp/Pml+
Trp53tm3.1Glo/Trp53+

(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
increased T cell derived lymphoma incidence J:317504
Pmltm1Ppp/Pmltm1Ppp
Trp53tm3.1Glo/Trp53+

(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
increased T cell derived lymphoma incidence J:317504
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
increased T cell derived lymphoma incidence J:162378
Poats1C57BL/6JCrl/Poats1C57BL/6JCrl
(involves: C57BL/6JCrl * DBA/2JCrl)
increased adrenal gland tumor incidence J:131752
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
increased T cell derived lymphoma incidence J:153684
Pold1tm1.1Bdp/Pold1tm1.1Bdp
Poletm1.1Bdp/Poletm1.1Bdp

(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp)
increased T cell derived lymphoma incidence J:153684
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:100685
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)
increased T cell derived lymphoma incidence J:261973
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
Trp53tm1Brd/Trp53+

(involves: C57BL/6J * C57BL/6NTac)
increased T cell derived lymphoma incidence J:261973
Pomctm1Low/Pomc+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomc+
Tg(Pomc)#Low/0

(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
increased pituitary adenoma incidence J:119240
Pomctm1Low/Pomctm1Low
Tg(Pomc)#Low/0

(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
increased pituitary adenoma incidence J:119240
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
increased sebaceous gland adenoma incidence J:90337
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6)
increased pituitary adenoma incidence J:71406
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6)
increased pituitary adenoma incidence J:71406
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6)
increased mammary adenocarcinoma incidence J:84677
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
increased mammary adenocarcinoma incidence J:84677
increased pancreatic islet cell adenoma incidence J:84677
increased T cell derived lymphoma incidence J:84677
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
increased T cell derived lymphoma incidence J:77491
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ)
increased thyroid tumor incidence J:98799
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased thyroid tumor incidence J:160299
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(TPO-cre)1Shk/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
increased thyroid carcinoma incidence J:225245
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(Ghrhr-cre)3242Lsk/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased pituitary gland tumor incidence J:130264
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Tg(TPO-cre)1Shk/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
increased thyroid carcinoma incidence J:225245, J:241066
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid)
increased T cell derived lymphoma incidence J:6958
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid)
increased T cell derived lymphoma incidence J:109833, J:22026
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6)
increased T cell derived lymphoma incidence J:53765
Prltm1Hmn/Prltm1Hmn
(involves: 129S2/SvPas)
increased pituitary adenoma incidence J:79661
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd)
increased thyroid carcinoma incidence J:101609
Prlrtm1Cnp/Prlrtm1Cnp
Tg(C3-1-TAg)cJeg/0

(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
increased prostate intraepithelial neoplasia incidence J:84352
Pscatm1Witt/Psca+
Tg(TRAMP)8247Ng/0

(involves: 129/Sv * C57BL/6)
increased prostate gland adenocarcinoma incidence J:133908
increased prostate gland tumor incidence J:133908
increased prostate intraepithelial neoplasia incidence J:133908
Pscatm1Witt/Pscatm1Witt
Tg(TRAMP)8247Ng/0

(involves: 129/Sv * C57BL/6)
increased prostate gland adenocarcinoma incidence J:133908
increased prostate gland tumor incidence J:133908
increased prostate intraepithelial neoplasia incidence J:133908
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased testicular teratoma incidence J:112118
Ptentm1.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased adrenal gland tumor incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
increased mammary adenocarcinoma incidence J:110567
increased prostate gland tumor incidence J:110567
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
increased thyroid adenoma incidence J:170965
Ptentm1.1Hwu/Pten+
Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:212219
Ptentm1.1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:212219
Ptentm1.1Mro/Pten+
(Not Specified)
increased pheochromocytoma incidence J:236514
Ptentm1.1Mro/Pten+
Sdhbtm1.2Ics/Sdhb+

(involves: 129S2/SvPas * BALB/c * C57BL/6)
increased pheochromocytoma incidence J:236514
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(MMTVneu)202Mul/0
Tg(S100a4-cre)1Gle/0

(involves: FVB/N)
increased mammary adenocarcinoma incidence J:153747
increased mammary gland tumor incidence J:153747
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0

(involves: FVB/N)
increased mammary gland tumor incidence J:153747
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased adrenal gland tumor incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
Ptentm1Hwu/Pten+
Tg(ARR2/Pbsn-FGF8)3Prb/0
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:106650
increased prostate intraepithelial neoplasia incidence J:106650
Ptentm1Hwu/Pten+
Tg(KRT14-cre)#Smr/0

(involves: 129S4/SvJae * C57BL/6J * SJL/J)
increased mammary adenocarcinoma incidence J:138927
increased mammary gland tumor incidence J:138927
Ptentm1Hwu/Pten+
Tg(Nkx2-1-cre)2Sand/0

(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
increased thyroid tumor incidence J:197590
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:93902
Ptentm1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:212219
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
increased prostate gland adenocarcinoma incidence J:144810
increased prostate intraepithelial neoplasia incidence J:144810
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129S4/SvJae * 129S7/SvEvBrd)
increased granulosa cell tumor incidence J:142150, J:222579
Ptentm1Hwu/Ptentm1Hwu
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0

(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
increased prostate gland adenocarcinoma incidence J:172653
increased prostate intraepithelial neoplasia incidence J:172653
Ptentm1Hwu/Ptentm1Hwu
Ptpn1tm1Bpk/Ptpn1tm1Bpk
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:231906
increased prostate intraepithelial neoplasia incidence J:231906
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
Tg(TPO-cre)1Shk/0

(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
increased thyroid carcinoma incidence J:177181
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
increased prostate gland adenocarcinoma incidence J:261540
increased prostate intraepithelial neoplasia incidence J:261540
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0

(involves: 129S4/SvJae * FVB/N)
increased prostate gland tumor incidence J:106662
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0

(involves: 129S4/SvJae * C57BL/6J * SJL/J)
increased mammary adenocarcinoma incidence J:138927
increased mammary gland tumor incidence J:138927
increased thyroid tumor incidence J:138927
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)#Tfln/0

(involves: 129S4/SvJae)
increased fibroadenoma incidence J:78415
increased mammary adenocarcinoma incidence J:78415
increased mammary gland tumor incidence J:78415
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0

(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
increased thyroid adenoma incidence J:197590
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:142106
increased prostate gland tumor incidence J:142106
increased prostate intraepithelial neoplasia incidence J:138565
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:268934, J:184935, J:212219
increased prostate gland tumor incidence J:268934, J:172730, J:170965
increased prostate intraepithelial neoplasia incidence J:268934, J:131932, J:212219
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:93902, J:124208
increased prostate gland tumor incidence J:124208
increased prostate intraepithelial neoplasia incidence J:93902, J:106650
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?

(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
increased prostate gland adenocarcinoma incidence J:238768
increased prostate intraepithelial neoplasia incidence J:238768
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:102226
increased pancreatic intraepithelial neoplasia incidence J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic acinar cell carcinoma incidence J:102226
increased pancreatic ductal adenocarcinoma incidence J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pgc-cre,-secNluc)#Hcz/0

(involves: 129S4/SvJae)
increased mammary adenocarcinoma incidence J:338079
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
increased granulosa cell tumor incidence J:222579
increased ovarian carcinoma incidence J:222579
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
increased adrenal gland tumor incidence J:63478
increased fibroadenoma incidence J:63478
increased mammary adenocarcinoma incidence J:63478
increased mammary gland tumor incidence J:63478
increased prostate gland tumor incidence J:63478
increased T cell derived lymphoma incidence J:50437
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak)
increased adrenal gland tumor incidence J:93530
Ptentm1Mro/Pten+
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0

(involves: 129S2/SvPas * FVB)
increased pheochromocytoma incidence J:236514
Ptentm1Mro/Pten+
Tg(KLK3-cre)D4Trp/0

(involves: 129P2/OlaHsd * FVB)
increased prostate gland adenocarcinoma incidence J:99524
increased prostate gland tumor incidence J:99524
increased prostate intraepithelial neoplasia incidence J:99524
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0

(involves: C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:184533
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0

(involves: 129S2/SvPas * FVB)
increased pheochromocytoma incidence J:236514
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhbtm1.2Ics
Tg(KLK3-cre)D4Trp/0

(involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB)
increased pheochromocytoma incidence J:236514
Ptentm1Ppp/Pten+
Tg(Pbsn-TAg)15Tvd/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:103408
increased prostate gland tumor incidence J:103408
increased prostate intraepithelial neoplasia incidence J:103408
Ptentm1Ppp/Ptentm2Ppp
(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:86212
Ptentm1Rdp/Ptentm1Rdp
Smad4tm1Rdp/Smad4tm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129 * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Tert+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Terttm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Terttm3Rdp/Terttm3Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
Ptentm1Rdp/Ptentm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J)
increased prostate intraepithelial neoplasia incidence J:53065
increased thyroid carcinoma incidence J:53065
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
increased prostate intraepithelial neoplasia incidence J:75085
Ptentm1Rps/Pten+
Tg(Wnt1)1Hev/0

(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
increased mammary adenocarcinoma incidence J:67497
increased mammary gland ductal carcinoma incidence J:67497
increased salivary adenocarcinoma incidence J:67497
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
increased adrenal gland tumor incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
Ptentm2.1Ppp/Pten+
Spry1tm1Jdli/Spry1tm1.1Jdli
Spry2tm1Mrt/Spry2tm1.1Mrt
Tg(Osr1-cre)4Mrt/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
increased prostate gland tumor incidence J:192348
increased prostate intraepithelial neoplasia incidence J:192348
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:307910
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0
Tg(Osr1-cre)4Mrt/0

(involves: 129P2/OlaHsd * 129S1/Sv * FVB/N)
increased prostate intraepithelial neoplasia incidence J:192348
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Osr1-cre)4Mrt/0

(involves: 129S1/Sv * 129X1/SvJ)
increased prostate intraepithelial neoplasia incidence J:192348
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:163589, J:100683
increased prostate gland tumor incidence J:86212, J:100683
increased prostate intraepithelial neoplasia incidence J:239660, J:163589, J:100683, J:200002
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)8113ANg/0

(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:86212
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0

(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk)
increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0

(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp)
increased thyroid carcinoma incidence J:211100
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * C57BL/6 * DBA/2)
increased prostate gland tumor incidence J:100683
Ptentm2Mak/Ptentm2Mak
Tg(KLK3-cre)13Saa/0

(involves: 129P2/OlaHsd * C57BL/6)
increased prostate gland adenocarcinoma incidence J:214242
increased prostate gland tumor incidence J:214242
increased prostate intraepithelial neoplasia incidence J:214242
Ptentm2Mak/Ptentm2Mak
Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased mammary gland tumor incidence in breeding females J:224955
Ptentm2Mak/Ptentm2Mak
Tg(Wap-cre)11738Mam/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased mammary gland tumor incidence in breeding females J:224955
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)11738Mam/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
Ptpn11tm1Ckq/Ptpn11+
Tg(Lck-cre)1Cwi/0

(involves: 129S6/SvEvTac * C57BL/6J)
increased lymphoblastic lymphoma incidence J:177285
Ptpn11tm1Ckq/Ptpn11+
Tg(Mx1-cre)1Cgn/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)
increased lymphoblastic lymphoma incidence J:177285
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)2964Rmp/?

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:64671
Ptprctm1Holm/Ptprctm1Holm
Tg(Lck*F505)3073Rmp/?

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:64671
Puf60tm1.1Kmtsu/Puf60+
Trp53tm1Sia/Trp53tm1Sia

(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)
increased T cell derived lymphoma incidence J:233347
Rad50tm2Jpt/Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
increased T cell derived lymphoma incidence J:78820
Rad50tm2Jpt/Rad50tm2Jpt
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:78820
Rag1tm1Jsek/Rag1tm1Jsek
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:146912
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Prf1tm1Sdz/Prf1tm1Sdz

(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
increased T cell derived lymphoma incidence J:109843
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0

(involves: 129/Sv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0

(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S7/SvEvBrd * C57BL)
increased pituitary adenoma incidence J:141515
increased T cell derived lymphoma incidence J:141515
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr

(involves: 129S7/SvEvBrd * C57BL)
increased T cell derived lymphoma incidence J:141515
Rag2tm1.1Desi/Rag2tm1.1Desi
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:168974
Rag2tm1.1Mss/Rag2tm1.1Mss
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:170462
Rag2tm1Fwa/Rag2+
Tg(LPV-TAg1135)11Tvd/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2+
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2tm1Fwa
Stat1tm1Rds/Stat1tm1Rds

(involves: 129S/SvEv * 129S6/SvEvTac)
increased mammary adenocarcinoma incidence J:216040
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0

(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
increased T cell derived lymphoma incidence J:235890
increased thymus tumor incidence J:235890
Rag2tm1Fwa/Rag2tm1Fwa
Tg(LPV-TAg1135)11Tvd/0

(involves: 129S/SvEv * C57BL/6 * DBA/2)
increased T cell derived lymphoma incidence J:47667
Rag2tm1Fwa/Rag2tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
increased T cell derived lymphoma incidence J:47667
Rag2tm2.1Desi/Rag2tm2.1Desi
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:168974
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Tg(MMTVneu)202Mul/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N)
increased mammary adenocarcinoma incidence J:202603
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
Trp53tm1Tyj/Trp53tm1Tyj

(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
increased testicular teratoma incidence J:102483
Rb1tm1Brd/Rb1+
(involves: 129S7/SvEvBrd * C57BL/6)
increased pituitary adenoma incidence J:17434
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
increased pheochromocytoma incidence J:79016
increased pituitary adenohypophysis tumor incidence J:79016
increased pituitary melanotroph tumor incidence J:79016
increased thyroid C-cell carcinoma incidence J:79016
Rb1tm1Brn/Rb1+
Tg(Pomc-FLP)1aBrn/0

(involves: 129P2/OlaHsd * FVB/N)
increased pituitary adenoma incidence J:48860
Rb1tm1Brn/Rb1tm1Brn
Tg(Pomc-FLP)1aBrn/0

(involves: 129P2/OlaHsd * FVB/N)
increased pituitary adenoma incidence J:48860
Rb1tm1Brn/Rb1tm1Brn
X/Tg(Pomc-FLP)1bBrn

(involves: 129P2/OlaHsd * FVB/N)
increased pituitary adenoma incidence J:48860
Rb1tm1Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
increased pituitary melanotroph tumor incidence J:20542
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
increased pituitary gland tumor incidence J:81082, J:2511
increased thyroid tumor incidence J:81082
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J)
increased pheochromocytoma incidence J:133299
increased pituitary adenohypophysis tumor incidence J:133299
increased pituitary melanotroph tumor incidence J:133299
increased thyroid C-cell carcinoma incidence J:133299
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
increased pituitary gland tumor incidence J:175625
increased thyroid tumor incidence J:175625
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas)
increased pituitary gland tumor incidence J:215358
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1+

(involves: 129S2/SvPas * C57BL/6)
increased pituitary gland tumor incidence J:34058
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1tm1Tyj

(involves: 129S2/SvPas * C57BL/6)
increased pituitary gland tumor incidence J:34058
Rb1tm1Tyj/Rb1+
Smarca4tm1Mag/Smarca4+

(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
increased pituitary gland tumor incidence J:132091
Rb1tm1Tyj/Rb1+
Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi

(involves: 129P2/OlaHsd * C57BL/6)
increased pituitary gland tumor incidence J:189317
increased thyroid tumor incidence J:189317
Rb1tm1Tyj/Rb1+
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * C57BL/6)
increased pancreatic islet cell carcinoma incidence J:19542
increased pituitary melanotroph tumor incidence J:19542
increased thyroid tumor incidence J:19542
Rb1tm1Tyj/Rb1tm2Tyj
(chimera involves: 129S2/SvPas * C57BL/6)
increased pituitary adenoma incidence J:59268
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0

(involves: 129 * FVB/N)
increased pituitary gland tumor incidence J:187257
Rb1tm2Brn/Rb1tm2Brn
Tg(Rbp3-cre)1Brn/0

(involves: 129 * FVB/N)
increased pituitary adenohypophysis tumor incidence J:77982
increased pituitary melanotroph tumor incidence J:77982
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53+

(involves: 129P2/OlaHsd)
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd)
increased ovarian carcinoma incidence J:84345
increased ovary tumor incidence J:84345
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0

(involves: 129 * 129P2/OlaHsd * FVB/N)
increased pituitary gland tumor incidence J:187257
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0

(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn)
increased mammary gland tumor incidence J:165292
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Ren-cre)#Kwg/0

(involves: 129 * 129P2/OlaHsd)
increased glucagonoma incidence J:216559
increased pancreatic islet cell carcinoma incidence J:216559
Rb1tm2Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
increased pituitary melanotroph tumor incidence J:20542
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Nes-cre)1Atp/0

(involves: 129S4/SvJae * FVB/N)
increased pituitary gland tumor incidence J:91406
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Atp/0

(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
increased pituitary gland tumor incidence J:91406
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu)
increased T cell derived lymphoma incidence J:189087
Rettm1Giro/Ret+
(129.129P2-Rettm1Giro)
increased thyroid adenoma incidence J:141658
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J * FVB/N)
increased pheochromocytoma incidence J:60659
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J)
increased pheochromocytoma incidence J:148708
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Tg(MMTV-cre)1Mam/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB)
increased mammary gland tumor incidence J:158922
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)1Mam/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:158922
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53tm1Brd
Tg(MMTV-cre)1Mam/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
increased T cell derived lymphoma incidence J:158922
Rgs5tm1.1Rgan/Rgs5tm1.1Rgan
Tg(RIP1-Tag)5Dh/0

(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
increased insulinoma incidence J:136259
Rgsc142/Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased T cell derived lymphoma incidence J:133634
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased pituitary adenoma incidence J:133634
increased thyroid carcinoma incidence J:133634
Rgsc1324/Rgsc1324+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased pheochromocytoma incidence J:133634
Rgsc1328/Rgsc1328+
(involves: C57BL/6JJcl * DBA/2JJcl)
increased pheochromocytoma incidence J:133634
Rhoctm1Mak/Rhoctm1Mak
Tg(MMTV-PyVT)634Mul/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:100482
Rint1tm1Whl/Rint1+
(Not Specified)
increased mammary adenocarcinoma incidence J:122805
increased mammary gland tumor incidence J:122805
increased ovary tumor incidence J:122805
increased pituitary adenoma incidence J:122805
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
increased mammary adenocarcinoma incidence J:161240
increased T cell derived lymphoma incidence J:161240
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
increased mammary adenocarcinoma incidence J:161240
increased T cell derived lymphoma incidence J:161240
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho
Tg(Ins2-Akt1*)3Mbb/0

(B6.Cg-Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb)
increased insulinoma incidence J:144599
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * C57BL/6N)
increased T cell derived lymphoma incidence J:223276
Rr149356tm1Che/Rr149356tm1Che
Tcrdtm1Mom/Tcrdtm1Mom
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:106246
Rr149356tm1Che/Rr149356tm1Che
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:106246
Runx1tm1(RUNX1)Gcg/Runx1tm1(RUNX1)Gcg
Tg(Mx1-cre)1Cgn/0

(involves: 129S1/Sv * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:106800
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))
increased T cell derived lymphoma incidence J:80829
Runx1tm2Buch/Runx1tm2Buch
Tg(Mx1-cre)1Cgn/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:105709
Runx1tm3Dow/Runx1+
Tg(Mx1-cre)1Cgn/0

(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:77129
Rxratm1Krc/Rxra+
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:78553
Rxratm1Krc/Rxratm1Krc
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:78553
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
increased mammary adenocarcinoma incidence J:89563
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ)
increased ovary tumor incidence J:160325
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0

(involves: FVB/NCrl)
increased prostate intraepithelial neoplasia incidence J:178461
Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * MOLF/Ei)
increased testis tumor incidence J:164224
Shc1tm5Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Shc1tm5Paw/Shc1tm5Paw
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Shc1tm6Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Shc1tm6Paw/Shc1tm6Paw
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Shc1tm7Paw/Shc1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss))
increased mammary gland tumor incidence J:177486
increased pancreas tumor incidence J:177486
increased prostate gland tumor incidence J:177486
Skiltm1Sis/Skil+
(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:62174
Smad4m4Mag/Smad4+
(involves: 129S/Sv * Black Swiss * C57BL/6)
increased ovary tumor incidence J:106440
Smad4tm1.1Gsu/Smad4tm1.1Gsu
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MtTGFA)Lmb/0

(involves: 129S1/Sv * 129X1/SvJ * CD-1)
increased pancreatic intraepithelial neoplasia incidence J:229184
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N)
increased mammary adenocarcinoma incidence J:212549
Smarca2tm1Mya/Smarca2tm1Mya
Smarca4tm1Mag/Smarca4+

(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
increased mammary gland tumor incidence J:132091
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1)
increased mammary adenocarcinoma incidence J:132091
Smarcb1tm1Sho/Smarcb1tm3Sho
Tg(Mx1-cre)1Cgn/?

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:80224
Spi1tm1.1Dgt/Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ)
increased T cell derived lymphoma incidence J:90331
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
increased T cell derived lymphoma incidence J:106040
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6)
increased T cell derived lymphoma incidence J:90331
Spry1tm1Jdli/Spry1tm1.1Jdli
Spry2tm1Mrt/Spry2tm1.1Mrt
Tg(Osr1-cre)4Mrt/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
increased prostate intraepithelial neoplasia incidence J:192348
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac)
increased adrenal cortical tumor incidence J:166879
increased ovary tumor incidence J:166879
increased testis tumor incidence J:166879
increased thyroid carcinoma incidence J:166879
Srctm1Mul/Src+
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:181822
Srctm1Mul/Srctm1Mul
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:181822
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased T cell derived lymphoma incidence J:119999
Ssbp2tm1Lana/Ssbp2tm1Lana
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)
increased T cell derived lymphoma incidence J:162035
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
increased mammary adenocarcinoma incidence J:216040
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
increased mammary adenocarcinoma incidence J:216040
Stat3tm4Vpo/Stat3tm4Vpo
Tg(MMTV-Erbb2)1Pv/0

(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA)
increased mammary adenocarcinoma incidence J:157976
increased mammary gland tumor incidence J:157976
Stk3tm1.1Jav/Stk3tm1.1Jav
(involves: 129 * C57BL/6)
increased mammary gland tumor incidence J:153945
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S7/SvEvBrd * 129X1/SvJ)
increased ovary tumor incidence J:107275
Stk11tm1Rdp/Stk11tm1Rdp
Tg(MMTV-Erbb2*,-cre)1Mul/0

(involves: 129S6/SvEvTac * C57BL/6)
increased mammary gland tumor incidence J:198481
Stk38tm1Hem/Stk38+
(involves: 129P2/Ola * C57BL/6)
increased T cell derived lymphoma incidence J:185408
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
increased T cell derived lymphoma incidence J:185408
Suprmam1BALB/cMed/Suprmam1BALB/cMed
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * BALB/cMed * C57BL/6 * C57BL/6J)
increased mammary gland tumor incidence J:122161
T(9;17)138Ca/T(9;17)138Ca
(Not Specified)
increased mammary gland tumor incidence J:169366
Tbrg1tm1a(KOMP)Wtsi/Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi)
increased Harderian gland adenoma incidence J:225146
Tbx21tm1Glm/Tbx21tm1Glm
Tg(TRAMP)8247Ng/0

(involves: 129S6/SvEvTac * C57BL/6)
increased prostate gland adenocarcinoma incidence J:88093
increased prostate gland tumor incidence J:88093
increased prostate intraepithelial neoplasia incidence J:88093
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6)
increased T cell derived lymphoma incidence J:44278
Tcf3tm2Wein/Tcf3tm2Wein
(Not Specified)
increased T cell derived lymphoma incidence J:47671
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
increased mammary adenoacanthoma incidence J:57721
Tg(ACTB-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
increased adrenal gland tumor incidence J:90843
Tg(AMH-Fshr)27Hht/0
(involves: FVB/N)
increased ovarian teratoma incidence J:160015
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N)
increased ovarian carcinoma incidence J:160015
increased ovarian teratoma incidence J:160015
increased prolactinoma incidence J:160015
Tg(AMH-Fshr*D580Y)#Hht/0
(involves: FVB/N)
increased ovarian teratoma incidence J:160015
Tg(Amh-SMAD2*)#Jebu/0
(FVB/N-Tg(Amh-SMAD2*)#Jebu)
increased ovarian teratoma incidence J:200783
increased ovary tumor incidence J:200783
Tg(Amh-SMAD2*)#Jebu/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * FVB/N)
increased ovarian teratoma incidence J:200783
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1)
increased ovarian carcinoma incidence J:82550
increased ovary tumor incidence J:82550
increased testis tumor incidence J:82550
Tg(APOE-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
increased adrenal gland tumor incidence J:90843
Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:106650, J:78918
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
(involves: FVB)
increased prostate intraepithelial neoplasia incidence J:87067
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
Tg(Pbsn-FGFR2_iiib*)#Ng/0

(involves: FVB)
increased prostate intraepithelial neoplasia incidence J:87067
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N)
increased prostate gland adenocarcinoma incidence J:223213, J:85480
increased prostate gland tumor incidence J:85480
increased prostate intraepithelial neoplasia incidence J:223213, J:85480
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
increased T cell derived lymphoma incidence J:93111
Tg(BCL2OVARY)1Ah/0
(involves: FVB)
increased ovarian teratoma incidence J:55158
Tg(BLG-STAT5A)6Itb/0
(involves: FVB/N)
increased mammary gland tumor incidence J:80588
Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
increased mammary gland tumor incidence J:80588
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N)
increased bulbourethral gland adenocarcinoma incidence J:46513
increased mammary adenocarcinoma incidence J:52786, J:46513
increased prostate gland adenocarcinoma incidence J:52786, J:46513, J:72324
increased prostate intraepithelial neoplasia incidence J:46513, J:72324
Tg(C3-1-TAg)cJeg/0
(FVB/N-Tg(C3-1-TAg)cJeg)
increased prostate gland tumor incidence J:84352
increased prostate intraepithelial neoplasia incidence J:84352
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0

(involves: 129P2/OlaHsd * FVB/N)
increased pancreas tumor incidence J:197052
increased pancreatic ductal adenocarcinoma incidence J:197052
increased pancreatic intraepithelial neoplasia incidence J:197052
Tg(CAG-cat,-ALOX15)1868Klv/0
Tg(Pbsn-cre)4Prb/0

(involves: C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:114903
Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv
Tg(Pbsn-cre)4Prb/?

(involves: C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:114903
Tg(CAG-Has2)99Nita/0
Tg(MMTV-cre)4Mam/0
Tg(MMTVneu)202Mul/0

(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
increased mammary adenocarcinoma incidence J:130531, J:164205
increased mammary gland tumor incidence J:164205
Tg(CAG-Has2)99Nita/0
Tg(MMTVneu)202Mul/0

(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
increased mammary adenocarcinoma incidence J:130531
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N)
increased ovarian carcinoma incidence J:158388
increased ovary tumor incidence J:158388
increased pancreas tumor incidence J:158388
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
increased T cell derived lymphoma incidence J:93665
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
increased lymphoblastic lymphoma incidence J:82127
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: C57BL/6 * Swiss Webster)
increased thymus tumor incidence J:235890
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0

(involves: C57BL/6 * Swiss Webster)
increased T cell derived lymphoma incidence J:235890
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N)
increased ovary tumor incidence J:207960
increased pancreatic acinar cell carcinoma incidence J:207960
Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
increased ovary tumor incidence J:55157
Tg(CMV-tTA)3Bjd/0
Tg(tetO-Prkar1a*x2as)1Stra/0

(involves: C57BL/6 * NMRI * SJL)
increased thyroid adenoma incidence J:95465, J:94953
Tg(Cyp19)C2-3Rrte/0
(involves: BALB/c * C57BL/6)
increased fibroadenoma incidence J:34063
increased mammary gland tumor incidence J:78693
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL)
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL)
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL)
increased pancreas tumor incidence J:76992
increased pancreatic acinar cell carcinoma incidence J:76992
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
increased insulinoma incidence J:76995
increased pancreas tumor incidence J:76995
increased pancreatic acinar cell carcinoma incidence J:76995
increased pancreatic islet cell adenoma incidence J:76995
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL)
increased insulinoma incidence J:76995
increased pancreas tumor incidence J:76995
increased pancreatic acinar cell carcinoma incidence J:76995
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2)
increased pancreas adenoma incidence J:78026
increased pancreas tumor incidence J:78026
increased pancreatic acinar cell carcinoma incidence J:78026
Tg(Ela1-TAg*)79Mjt/0
Tg(MUC1)79.24Gend/0

(involves: C57BL/6 * DBA/2)
increased pancreas adenoma incidence J:64570
increased pancreas tumor incidence J:64570
increased pancreatic acinar cell carcinoma incidence J:64570
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2)
increased pancreas adenoma incidence J:78026
increased pancreas tumor incidence J:78026
increased pancreatic acinar cell carcinoma incidence J:78026
Tg(Ela1-Tgfa)150Bri/0
(involves: C57BL/6 * SJL)
increased pancreas tumor incidence J:52757, J:67389
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
increased pancreas tumor incidence J:67389
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
increased pancreas tumor incidence J:67389
increased pancreatic ductal adenocarcinoma incidence J:67389
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
increased pancreas tumor incidence J:231759
Tg(Ela-KRAS*G12D)9Eps/0
Tg(Mt1-TGFBR2*)AM3Epb/0

(involves: C57BL/6 * FVB)
increased pancreas tumor incidence J:231759
Tg(Ela-KRAS*G12D)9Eps/0
Tgfbr1tm1Bopa/Tgfbr1+

(involves: 129S1/SvImJ * C57BL/6 * FVB)
increased pancreas tumor incidence J:231759
Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA)
increased T cell derived lymphoma incidence J:79624
Tg(Erbb2*)#Maed/0
Tg(Foxa3-cre)1Khk/0

(involves: C57BL/6 * C57BL/6J * DBA)
increased pancreas tumor incidence J:262746
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:62441
increased mammary gland tumor incidence in breeding females J:62441
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1)
increased pancreas tumor incidence J:91490, J:101537
Tg(Ggamma-T)15Cps/0
(involves: C57BL/6J * CBA/J)
increased adrenal gland tumor incidence J:38778
increased prostate gland tumor incidence J:38778
increased prostate intraepithelial neoplasia incidence J:38778
increased testis tumor incidence J:38778
Tg(Ggamma-T)15Cps/Tg(Ggamma-T)15Cps
(involves: C57BL/6J * CBA/J)
increased adrenal gland tumor incidence J:38778
increased prostate gland tumor incidence J:38778
increased prostate intraepithelial neoplasia incidence J:38778
increased testis tumor incidence J:38778
Tg(Gh-Gal)4599Vron/?
(involves: C57BL/6 * CD-1 * SJL)
increased pituitary adenoma incidence J:86486
Tg(GHRL-TAg)1-5Hiwa/0
(C57BL/6-Tg(GHRL-TAg)1-5Hiwa)
increased pancreas tumor incidence J:152492
increased thyroid tumor incidence J:152492
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
increased prostate gland adenocarcinoma incidence J:206727, J:184212
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0

(involves: FVB/N)
increased prostate gland adenocarcinoma incidence J:206727
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
increased T cell derived lymphoma incidence J:178816
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
increased lymphoblastic lymphoma incidence J:109591
Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA)
increased T cell derived lymphoma incidence J:79624
Tg(Ins1-Tag,-luc)1Gcr/0
(FVB/N-Tg(Ins1-Tag,-luc)1Gcr)
increased insulinoma incidence J:162648
Tg(Ins1-Tag,-luc)1Gcr/0
(involves: C57BL/6 * FVB/N)
increased insulinoma incidence J:162648
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb)
increased insulinoma incidence J:144599
increased pancreas tumor incidence J:144599
increased pancreatic islet cell carcinoma incidence J:144599
Tg(Ins2-IGF1R)1Dh/0
Tg(RIP1-Tag)2Dh/0

(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J)
increased insulinoma incidence J:205389
increased pancreatic islet cell carcinoma incidence J:205389
Tg(Ins2-rtTA)2Efr/0
Tg(tetO-TAg)1Efr/0

(involves: C3HeB/FeJ * C57BL/6 * CBA)
increased insulinoma incidence J:130049
Tg(Ins2-TAg)1Lt/0
(NOD/ShiLt-Tg(Ins2-TAg)1Lt)
increased insulinoma incidence J:92449
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J)
increased insulinoma incidence J:187012
increased pancreas tumor incidence J:187012
increased pancreatic islet cell carcinoma incidence J:187012
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified)
increased pancreatic islet cell carcinoma incidence J:188693
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI)
increased sebaceous gland adenoma incidence J:79071
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI)
increased sebaceous gland adenoma incidence J:79071
Tg(KRT14-Edn3)1Takk/?
(B6.Cg-Tg(KRT14-Edn3)1Takk)
increased thyroid tumor incidence J:104881
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N)
increased sebaceous gland tumor incidence J:86018
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1)
increased sebaceous gland tumor incidence J:229072
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2)
increased ovarian carcinoma incidence J:189304
increased ovary tumor incidence J:189304
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N)
increased adrenal gland tumor incidence J:64395
increased prostate gland tumor incidence J:64395
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
increased T cell derived lymphoma incidence J:88120
Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6)
increased T cell derived lymphoma incidence J:73487
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6)
increased T cell derived lymphoma incidence J:73487
Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified)
increased T cell derived lymphoma incidence J:144975
Tg(Lck-Akt2*)#Test/0
(Not Specified)
increased T cell derived lymphoma incidence J:153923
Tg(Lck-Id1)28Xhsu/0
(Not Specified)
increased T cell derived lymphoma incidence J:58607
Tg(Lck-LMO1)11Sjk/0
Tg(STIL-TAL1)A5(3)Alpa/0

(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
increased T cell derived lymphoma incidence J:40868
Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J)
increased T cell derived lymphoma incidence J:39450
Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2)
increased lymphoblastic lymphoma incidence J:63300
increased T cell derived lymphoma incidence J:96010
Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led)
increased lymphoblastic lymphoma incidence J:36076
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
increased T cell derived lymphoma incidence J:129531
Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J)
increased T cell derived lymphoma incidence J:93005
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
increased T cell derived lymphoma incidence J:28635
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
increased testis tumor incidence J:144382
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
increased testis tumor incidence J:144382
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:69755
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6)
increased pituitary adenoma incidence J:51661
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:145680
increased ovary tumor incidence J:145680
Tg(MMTV-AURKA)#Cxd/?
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * FVB/N)
increased mammary adenocarcinoma incidence J:145680
Tg(MMTV-CCND1)1Esmp/0
(Not Specified)
increased mammary adenoacanthoma incidence J:70571
increased mammary adenocarcinoma incidence J:70571
increased mammary gland tumor incidence J:70571
increased testis tumor incidence J:70571
Tg(MMTV-CCND1)1Esmp/0
Tg(MMTV-Cdc37)1Stp/0

(involves: C57BL/6 * DBA/2 * FVB/N)
increased mammary adenocarcinoma incidence J:62465
increased mammary gland tumor incidence J:62465
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
increased mammary adenoacanthoma incidence J:62465
increased mammary adenocarcinoma incidence J:62465
Tg(MMTV-Cdc37)1Stp/0
Tg(MMTV-Myc)141-3Led/0

(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N)
increased Leydig cell tumor incidence J:62465
increased mammary adenocarcinoma incidence J:62465
increased mammary gland tumor incidence J:62465
increased salivary adenocarcinoma incidence J:62465
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
increased mammary adenoacanthoma incidence J:62465
Tg(MMTV-DMTF1_i2)7Kai/0
(FVB/NJ-Tg(MMTV-DMTF1_i2)7Kai)
increased mammary gland tumor incidence in breeding females J:220608
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA)
increased mammary adenocarcinoma incidence J:234420
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick)
increased Harderian gland adenoma incidence J:90202
increased mammary adenocarcinoma incidence J:90202
increased mammary gland tumor incidence J:90202
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
increased Harderian gland tumor incidence J:72129
increased mammary adenocarcinoma incidence J:72129
increased salivary gland tumor incidence J:72129
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
increased mammary adenocarcinoma incidence J:72129
increased salivary gland tumor incidence J:72129
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
increased mammary adenocarcinoma incidence J:72129
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N)
increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul)
increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:48632
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:76653
Tg(MMTV-Erbb2)NK1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NK1Mul)
increased mammary gland tumor incidence J:67457
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: C57BL/6)
increased mammary gland tumor incidence J:189292
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased mammary gland tumor incidence J:133325
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: FVB)
increased mammary gland tumor incidence J:198481
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami)
increased mammary adenocarcinoma incidence J:172352
increased mammary gland tumor incidence J:172352
Tg(MMTV-ERBB2*,-luc)6177Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6177Aami)
increased mammary gland tumor incidence J:172352
Tg(MMTV-ERBB2*,-luc)6180Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6180Aami)
increased mammary gland tumor incidence J:172352
Tg(MMTV-ERBB3)1Slg/0
Tg(MMTVneu)202Mul/0

(involves: FVB)
increased mammary gland tumor incidence J:80974
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6)
increased mammary adenocarcinoma incidence J:216267
increased mammary gland tumor incidence in breeding females J:216267
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL)
increased mammary adenocarcinoma incidence J:77272
Tg(MMTV-KRAS*G12V)3025Mrl/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-MYC)1Lach/0

(involves: C57BL/6 * FVB/N * SJL)
increased mammary gland tumor incidence J:133578
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
increased mammary adenocarcinoma incidence J:149661
increased mammary gland tumor incidence in breeding females J:149661
Tg(MMTV-Myc)141-3Led/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0

(involves: C57BL/6J * CD-1 * FVB/N)
increased mammary gland tumor incidence J:133578
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(MMTV-Myc*T58A)TA39Jrn/0
(involves: FVB)
increased mammary gland tumor incidence J:193362
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:153233
increased mammary gland tumor incidence J:153233, J:193362
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr)
increased mammary adenocarcinoma incidence J:93548
increased mammary gland tumor incidence J:93548
increased pituitary adenoma incidence J:93548
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
(involves: C57BL/6)
increased mammary gland tumor incidence J:122846
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
Tg(Trp53R172H)8512Jmr/?

(involves: C57BL/6 * FVB)
increased mammary adenocarcinoma incidence J:122846
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:11644
increased salivary adenocarcinoma incidence J:11644
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1)
increased mammary adenocarcinoma incidence J:68565
increased mammary gland ductal carcinoma incidence J:68565
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci)
increased mammary adenocarcinoma incidence J:46460, J:51424, J:87544, J:48285
Tg(MMTV-PyVT)634Mul/0
(multiple strains)
increased mammary adenocarcinoma incidence J:48854
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/J)
increased mammary gland tumor incidence J:140033, J:147458
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
increased mammary gland tumor incidence J:147458
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/N)
increased mammary gland tumor incidence J:133325, J:236031
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
increased mammary adenocarcinoma incidence J:147923
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul)
increased mammary adenocarcinoma incidence J:56327
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul)
increased mammary adenocarcinoma incidence J:56327
Tg(MMTV-rtTA)1Lach/0
Tg(TetO-Erbb2)1Lach/0

(involves: FVB)
increased mammary adenocarcinoma incidence J:81083
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-ERBB2)#Jjz/0

(involves: FVB/N)
increased mammary adenocarcinoma incidence J:231766
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0

(involves: FVB/N)
increased mammary gland ductal carcinoma incidence J:96383
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-IGF1R)1Ramo/0

(involves: FVB)
increased mammary adenocarcinoma incidence J:121069
increased mammary gland tumor incidence J:121069
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0

(involves: FVB/N)
increased mammary gland tumor incidence J:133578
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
Tg(tetO-MYC)1Lach/0

(involves: FVB/N)
increased mammary gland tumor incidence J:133578
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-MYC)1Lach/0

(involves: FVB)
increased mammary adenocarcinoma incidence J:67498
increased mammary gland tumor incidence J:133578, J:67498
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0

(involves: FVB/N)
increased mammary adenocarcinoma incidence J:175839
increased mammary gland tumor incidence J:175839
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-PyVT,-cre)1Mul/0

(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul)
increased mammary adenocarcinoma incidence J:231983
increased mammary gland tumor incidence in virgin females J:231983
Tg(MMTV-TGFBR2)7Hlm/?
Tg(MMTVTGFA)29Rjc/?

(involves: C57BL/6 * DBA)
increased mammary adenocarcinoma incidence J:85799
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA)
increased mammary adenocarcinoma incidence J:85799
Tg(MMTV-vHaras)SH1Led/0
(involves: C57BL/6J * CD-1)
increased mammary gland tumor incidence J:88789
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB)
increased mammary adenocarcinoma incidence J:86074
Tg(MMTVneu)202Mul/0
(involves: FVB/N)
increased mammary gland tumor incidence J:35344, J:80974
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul)
increased mammary adenocarcinoma incidence J:56332
Tg(MMTVneu)202Mul/0
Tg(MMTVTGFA)29Rjc/0

(involves: C57BL/6 * DBA/2 * FVB/N)
increased mammary gland tumor incidence J:35344
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0

(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr)
increased mammary adenocarcinoma incidence J:115041
increased parotid gland tumor incidence J:115041
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0

(involves: FVB)
increased mammary gland tumor incidence J:40336
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2)
increased mammary adenocarcinoma incidence J:72085, J:72080, J:28453, J:71696
increased mammary gland tumor incidence J:28453, J:71696
Tg(MMTVTGFA)64Rjc/0
(involves: C57BL/6 * DBA/2)
increased mammary gland tumor incidence J:72085
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2)
increased mammary adenocarcinoma incidence J:72085
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
increased prostate gland adenocarcinoma incidence J:80313
increased prostate intraepithelial neoplasia incidence J:80313
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:56318
increased mammary gland tumor incidence J:56318
Tg(Mt1-Tgfa)149Bri/0
(involves: C57BL/6 * SJL)
increased pancreatic intraepithelial neoplasia incidence J:162125
Tg(MtTGFA)100Lmb/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:72083
increased mammary gland tumor incidence J:72083
Tg(MtTGFA)Lmb/0
(involves: CD-1)
increased pancreatic intraepithelial neoplasia incidence J:229184
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng)
increased mammary gland tumor incidence J:71573
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng)
increased mammary gland tumor incidence J:71573
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
increased adrenal gland tumor incidence J:54269
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N)
increased prostate gland adenocarcinoma incidence J:96117
increased prostate gland tumor incidence J:96117
Tg(Pbsn-ERG*)1Vv/0
(involves: 129/Sv * C57BL/6J * CBA)
increased prostate intraepithelial neoplasia incidence J:131932
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA)
increased prostate gland adenocarcinoma incidence J:222916
increased prostate gland tumor incidence J:222916
Tg(Pbsn-FGF7)3293Ng/0
(Not Specified)
increased prostate intraepithelial neoplasia incidence J:80821
Tg(Pbsn-FGFR1*K656E)#Wmck/0
(involves: FVB)
increased prostate intraepithelial neoplasia incidence J:87519
Tg(Pbsn-FGFR1*K656E)#Wmck/0
Tg(Pbsn-FGFR2_iiib*)#Ng/0

(involves: FVB)
increased prostate intraepithelial neoplasia incidence J:87067
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp)
increased prostate gland adenocarcinoma incidence J:130340
increased prostate gland tumor incidence J:130340
increased prostate intraepithelial neoplasia incidence J:130340, J:87092
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0

(involves: FVB/N)
increased prostate gland adenocarcinoma incidence J:206727
Tg(Pbsn-Hpn,-GFP)DVv/0
Tg(Pbsn-Tag)12T7fRjm/0

(involves: C57BL/6J * CBA * CD-1)
increased prostate gland adenocarcinoma incidence J:92562
increased prostate intraepithelial neoplasia incidence J:92562
Tg(Pbsn-IGF1*)5305Ng/0
(involves: FVB/N)
increased prostate intraepithelial neoplasia incidence J:144539
Tg(Pbsn-IGF1*)5305Ng/0
Tg(TRAMP)8247Ng/0

(involves: C57BL/6 * FVB/N)
increased prostate gland tumor incidence J:144539
Tg(Pbsn-MYC)6Key/?
(involves: FVB)
increased prostate gland adenocarcinoma incidence J:85480
increased prostate gland tumor incidence J:85480
increased prostate intraepithelial neoplasia incidence J:85480
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J)
increased prostate gland adenocarcinoma incidence J:205395
increased prostate intraepithelial neoplasia incidence J:205395
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1)
increased prostate gland adenocarcinoma incidence J:48623
increased prostate gland tumor incidence J:48623
increased prostate intraepithelial neoplasia incidence J:92562, J:48623
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1)
increased prostate gland adenocarcinoma incidence J:68483, J:48623
increased prostate gland tumor incidence J:48623
increased prostate intraepithelial neoplasia incidence J:68483
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:103408
increased prostate intraepithelial neoplasia incidence J:103408
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
increased T cell derived lymphoma incidence J:17848
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA)
increased insulinoma incidence J:185488
increased pancreas tumor incidence J:185488
Tg(Pklr-SV40)1Ak/Tg(Pklr-SV40)1Ak
(involves: C57BL/6 * DBA)
increased pancreas tumor incidence J:185488
Tg(Prl-EGFR)#Sme/0
(Not Specified)
increased prolactinoma incidence J:219654
Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar)
increased parathyroid adenoma incidence J:69423
Tg(PyLT)1Vb/0
(Not Specified)
increased pituitary adenoma incidence J:55528
increased pituitary gland tumor incidence J:55528
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6)
increased pineal gland tumor incidence J:60231
Tg(RIP1-Tag)2Dh/?
(C3.Cg-Tg(RIP1-Tag)2Dh/Nci)
increased insulinoma incidence J:80168
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
increased insulinoma incidence J:162648
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J)
increased insulinoma incidence J:205389
increased pancreas tumor incidence J:50695
increased pancreatic islet cell carcinoma incidence J:205389
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
increased insulinoma incidence J:80168
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
increased insulinoma incidence J:136259
Tg(RIR-Tag)87Dh/0
(involves: C57BL/6J * DBA/2J)
increased pancreas tumor incidence J:50695
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac)
increased adrenal gland tumor incidence J:90323
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J)
increased salivary adenocarcinoma incidence J:66189
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
increased T cell derived lymphoma incidence J:125150
Tg(SV)419Bri/Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri)
increased T cell derived lymphoma incidence J:147031
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
increased T cell derived lymphoma incidence J:55022
Tg(Tcra,Tcrb)HRVAll/0
Tg(TRAMP)8247Ng/0

(B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll)
increased prostate gland tumor incidence J:131347
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
increased T cell derived lymphoma incidence J:263520
Tg(tetO-BRAF*V600E)26Jaf/0
Tg(TG-rtTA)30Jaf/0

(involves: FVB/N)
increased thyroid carcinoma incidence J:184420
increased thyroid tumor incidence J:184420
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6)
increased adrenal gland tumor incidence J:175962
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf)
increased thyroid carcinoma incidence J:98550
increased thyroid tumor incidence J:98550
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf)
increased thyroid carcinoma incidence J:98550
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified)
increased thyroid adenoma incidence J:210016
increased thyroid carcinoma incidence J:210016
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N)
increased thyroid carcinoma incidence J:55883, J:93679
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N)
increased thyroid carcinoma incidence J:55883, J:93679
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6)
increased thyroid carcinoma incidence J:51366
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
increased thyroid carcinoma incidence J:209788
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6)
increased thyroid carcinoma incidence J:67120
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:210015
Tg(Th-TAg)17Dmc/0
((C57BL/6NTac x DBA/2NTac)F2)
increased adrenal gland tumor incidence J:90323
Tg(Thy1-cmyc)6Kio/0
(Not Specified)
increased T cell derived lymphoma incidence J:129440
Tg(Thy1-cmyc)6LKio/0
(Not Specified)
increased T cell derived lymphoma incidence J:129440
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
increased submandibular gland tumor incidence J:73711
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:108849
Tg(TRAMP)8247Ng/0
(involves: C57BL/6)
increased prostate gland adenocarcinoma incidence J:217920, J:65303
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
increased prostate gland adenocarcinoma incidence J:125633
increased prostate gland tumor incidence J:125633
increased prostate intraepithelial neoplasia incidence J:125633
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
increased prostate gland adenocarcinoma incidence J:133908
increased prostate gland tumor incidence J:133908
increased prostate intraepithelial neoplasia incidence J:133908, J:131932
Tg(TRAMP)8247Ng/0
Usp11tm1Tac/Y

(involves: 129 * C57BL/6)
increased prostate gland adenocarcinoma incidence J:270214
increased prostate intraepithelial neoplasia incidence J:270214
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
increased mammary adenocarcinoma incidence J:46426
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
increased T cell derived lymphoma incidence J:189197
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
increased T cell derived lymphoma incidence J:88565
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:86776
increased mammary gland tumor incidence in breeding females J:86776
increased mammary gland tumor incidence in virgin females J:86776
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig)
increased mammary adenocarcinoma incidence J:206839
increased mammary gland tumor incidence in breeding females J:206839
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL)
increased mammary gland tumor incidence J:46458
increased salivary adenocarcinoma incidence J:46458
X/Tg(Wap-HRAS)69Lln
(FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J)
increased mammary gland tumor incidence J:101113
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6)
increased mammary gland ductal carcinoma incidence J:61012
Tg(Wap-tAg)1Gmn/?
(involves: NMRI)
increased mammary adenocarcinoma incidence J:69711
Tg(Wap-TAg)12Gmn/?
(involves: NMRI)
increased mammary gland tumor incidence J:69711
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6)
increased mammary gland ductal carcinoma incidence J:61012
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw)
increased mammary adenocarcinoma incidence J:121475
Tg(WapMyc)212Bri/0
(FVB.Cg-Tg(WapMyc)212Bri)
increased mammary gland tumor incidence J:114568
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:56318
increased mammary gland tumor incidence J:56318
Tg(WapMyc)212Bri/0
Tg(WapTgfa)215Bri/0

(involves: C57BL/6 * SJL)
increased mammary gland tumor incidence J:56318
Tg(WapNotch4)10Rnc/0
(involves: FVB/N)
increased mammary adenocarcinoma incidence J:33193
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J)
increased mammary adenocarcinoma incidence J:53175
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw)
increased mammary adenocarcinoma incidence J:53175
Tg(WapTgfa)215Bri/0
(FVB.Cg-Tg(WapTgfa)215Bri)
increased mammary gland tumor incidence J:114568
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:56318
increased mammary gland tumor incidence J:56318
Tg(WapTgfa)215Bri/0
(B6.Cg-Tg(WapTgfa)215Bri)
increased mammary gland tumor incidence J:123146
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * FVB * SJL)
increased mammary gland tumor incidence J:96305
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:54215
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:61009
Tgct1MOLF/Ei/Tgct1MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
increased testis tumor incidence J:81573
Tgct2MOLF/Ei/Tgct2MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
increased testis tumor incidence J:81573
Tgct3MOLF/Ei/Tgct3MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
increased testis tumor incidence J:81573
Tgct5MOLF/Ei/Tgct5MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
increased testis tumor incidence J:81573
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:204736
increased prostate intraepithelial neoplasia incidence J:204736
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * C57BL/6)
increased mammary adenocarcinoma incidence J:72391
increased pancreas tumor incidence J:72391
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6)
increased pancreas tumor incidence J:72391
ThimTg(Myh6-TGFB1)1Ljf/Thim+
(involves: C3HeB/FeJ)
increased T cell derived lymphoma incidence J:59903
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
increased pituitary adenoma incidence J:95391
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:92629
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:92629
Thyls2MSM/Thyls2MSM
(involves: BALB/c * MSM)
increased T cell derived lymphoma incidence J:87704
Tlag2AKR/J/Tlag2C57L/J
(involves: AKR/J * C57L/J)
increased T cell derived lymphoma incidence J:74369
Tlag2AKR/J/Tlag2C57L/J
Tlag1AKR/J/Tlag1AKR/J

(involves: AKR/J * C57L/J)
increased T cell derived lymphoma incidence J:74369
Tlsm1AKR/JMs/Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh)
increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
Tlsm1AKR/JMs/Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh)
increased T cell derived lymphoma incidence J:21741, J:41197, J:33016
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6)
increased pancreas tumor incidence J:140639
Tom1l2Gt(XG909)Byg/Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
increased prostate gland tumor incidence J:133892
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
increased mammary gland tumor incidence J:133892
increased ovary tumor incidence J:133892
increased prostate gland tumor incidence J:133892
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
increased ovary tumor incidence J:232482
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6)
increased mammary adenocarcinoma incidence J:204336
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6)
increased mammary adenocarcinoma incidence J:204336
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
increased T cell derived lymphoma incidence J:104190
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
increased T cell derived lymphoma incidence J:104190
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
increased T cell derived lymphoma incidence J:173271
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased T cell derived lymphoma incidence J:198482
Trp53tm1.1Umol/Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
increased ovary tumor incidence J:173271
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
increased ovary tumor incidence J:173271
increased T cell derived lymphoma incidence J:173271
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:126497
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)1Cwi/0

(involves: 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:157041
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Kln/0

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
increased T cell derived lymphoma incidence J:109585
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:73757
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd)
increased mammary adenocarcinoma incidence J:170898
increased mammary gland tumor incidence J:170898
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:116152
increased mammary gland tumor incidence J:126551
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0

(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn)
increased mammary gland tumor incidence J:165292
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:162126
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:171765
increased mammary gland tumor incidence J:171765
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)AElee/0

(involves: 129S4/SvJae * C57BL/6)
increased mammary adenocarcinoma incidence J:90247
increased mammary gland tumor incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(MMTV-cre)BElee/0

(involves: 129S4/SvJae * C57BL/6)
increased mammary adenocarcinoma incidence J:90247
Trp53tm1Elee/Trp53tm1Elee
Tg(Wap-rtTA-cre)10Whl/0

(involves: 129S4/SvJae * C57BL/6)
increased mammary adenocarcinoma incidence J:90247
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6)
increased T cell derived lymphoma incidence J:99305
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:61683
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:171821
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:36762
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj)
increased T cell derived lymphoma incidence J:233347
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
increased T cell derived lymphoma incidence J:198482
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
increased mammary adenocarcinoma incidence J:72391
increased pancreas tumor incidence J:72391
Trp53tm1Tyj/Trp53+
Trp63tm1Fmc/Trp63+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased mammary adenocarcinoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp53tm1Tyj/Trp53+
Trp73tm1Fmc/Trp73+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
increased pancreatic acinar cell carcinoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp53tm1Tyj/Trp53+
Xrcc2tm1Pmc/Xrcc2tm1Pmc

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:111068
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:87501, J:17728
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:251434, J:221224, J:88120, J:95316
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
increased testicular teratoma incidence J:102483
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm1Pmc/Xrcc2tm1Pmc

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased T cell derived lymphoma incidence J:111068
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
increased T cell derived lymphoma incidence J:95316
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
increased T cell derived lymphoma incidence J:95316
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased T cell derived lymphoma incidence J:282255
increased testis tumor incidence J:282255
Trp53tm2.1Umol/Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
increased T cell derived lymphoma incidence J:228632
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased T cell derived lymphoma incidence J:282255
increased testis tumor incidence J:282255
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo)
increased T cell derived lymphoma incidence J:317504
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1)
increased mammary adenocarcinoma incidence J:121734
Trp53tm3Tyj/Trp53+
Tg(Wap-cre)11738Mam/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased mammary adenocarcinoma incidence J:101617
increased mammary gland tumor incidence J:101617
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
increased T cell derived lymphoma incidence J:171821
Trp53tm4Xu/Trp53tm4Xu
(Not Specified)
increased T cell derived lymphoma incidence J:126497
Trp53tm6Xu/Trp53tm6Xu
Tg(Lck-cre)1Cwi/0

(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:157041
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6)
increased T cell derived lymphoma incidence J:82512
Trp53bp2tm1Cdlo/Trp53bp2+
Tg(EmuSR-tTa)83Bop/0
Tg(tetO-MYC)36aBop/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased T cell derived lymphoma incidence J:146764
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
increased T cell derived lymphoma incidence J:108701
Trp63tm1Fmc/Trp63+
Trp73tm1Fmc/Trp73+

(involves: 129S4/SvJae * C57BL/6)
increased mammary adenocarcinoma incidence J:98958
increased salivary gland adenoma incidence J:98958
increased T cell derived lymphoma incidence J:98958
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:98958
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
increased T cell derived lymphoma incidence J:142848
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
increased T cell derived lymphoma incidence J:142848
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6)
increased T cell derived lymphoma incidence J:191827
Vhltm1Lss/Vhltm1Lss
Tg(Pdx1-cre)89.1Dam/0

(involves: 129X1/SvJ * C57BL/6 * CBA)
increased pancreas adenoma incidence J:148174
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
increased T cell derived lymphoma incidence J:44361
Zeb1tm1Yhi/Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))
increased T cell derived lymphoma incidence J:139194
Zfhx3tm1.1Jtd/Zfhx3tm1.1Jtd
Tg(Pbsn-cre)4Prb/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
increased prostate intraepithelial neoplasia incidence J:189563
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr
Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr
Tg(CD2-icre)4Kio/0

(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)
increased T cell derived lymphoma incidence J:162388

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory